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Abstract 
Exosomes/extracellular vesicles (EVs) are cell-derived mixed-populations of vesicles 
released by almost all cells into the intercellular microenvironment, ending up in the 
circulation. Exosomes contain proteins, RNAs and lipid molecules reflecting the status of 
the parental cell at the time of release, making them promising candidates for biomarker 
discovery. The contents of exosomes are protected by a lipid bilayer, leading to better 
stability of bio-macromolecules. Recent evidence suggests a novel role for exosomes as 
conveyors of information among cells and across tissues, through horizontal transfer of 
proteins, lipids, and nucleic acids. Exosomes have been the subject of numerous research in 
recent years; however, their roles still have to be identified in the pathogenesis of different 
diseases. 
 
MicroRNAs (miRNAs) are small (18-25 nucleotide long) non-coding RNAs which play 
pivotal roles in the gene expression process and it is estimated that about one third of the 
human genome is controlled by miRNAs. miRNA regulatory processes have been found to 
influence many essential biological pathways, such as cellular development, proliferation, 
apoptosis, and cellular signaling. A great proportion of miRNAs has been reported to be 
associated with the exosome function of different biofluids. 
 
The aim of this research was to elucidate the role of exosomes/EVs as well as miRNAs in 
the pathogenesis of different diseases, including alcoholic liver disease, hepatitis C, and 
cancer. This knowledge may lead to the development of novel molecular diagnostic 
approaches, as well as innovative drug delivery modalities for small RNA-targeted therapy. 
My research resulted in a) the establishment of new methods and approaches to the study of 
exosomes/EVs, as well as comparative literature on the efficacy of several isolation and 
characterization techniques. b) identification of the role of exosomes and miRNA-122 in the 
cross talk between hepatocytes and immune cells in alcoholic liver disease c) identification 
of the role of exosomes in HCV pathogenesis, including the potential of molecular therapies 
based on miRNA and exosome targeting in vitro and in vivo d) understanding the bio-
distribution of exosomes and miRNA in an in vivo murine model and f) exploring the utility 
of miRNA and exosomes in biofluids in cancer biomarker discovery. 
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Introduction 
Exosomes/extracellular vesicles (EVs) are heterogeneous membrane-coated vesicles 
released from almost all cell types into the microenvironment (Raposo and Stoorvogel, 2013; 
Mulcahy et al., 2014). The first reports on exosomes did not appreciate their biological value 
and role in cellular communication (Chargaff and West, 1946; Yanez-Mo et al., 2015). In 
the past decade, however, exosomes have emerged as major signaling molecule conveyors, 
delivering cargo (Mulcahy et al., 2014) that can modify recipient cell functions (Valadi et 
al., 2007; Yanez-Mo et al., 2015; Quesenberry et al., 2015). Several mechanisms of exosome 
internalization have been proposed, including clathrin-mediated endocytosis (CME), 
phagocytosis, micropinocytosis, and plasma membrane fusion (Mulcahy et al., 2014). Lipid 
rafts and specific protein–protein interactions have also been shown to play roles in exosome 
uptake (Mulcahy et al., 2014). The biological actions of exosomes can be mediated by 
different bio-macromolecules including lipids, proteins, glycans, and nucleic acids (Lotvall 
et al., 2014), playing roles in both physiological processes and disease pathogenesis. 
Exosome-contained bioactive molecules are also quite stable and protected against proteases 
as well as RNases, due to the presence of a lipid bilayer in EV structures (Valadi et al., 2007; 
Lambertz et al., 2015). Furthermore, these structures are stable under adverse physical 
conditions such as long-term storage, multiple freeze-thaw cycles, and extreme pH (Nawaz 
et al., 2014). As such characteristics match the criteria for selecting clinically-relevant 
biomarkers and drug delivery systems; interest in exosome biology is growing apace. 
 
Specifically, the absolute number of exosomes has been reported to increase in pathological 
conditions, and to be enriched with a specific set of biological markers (a biomarker 
signature) related to the cell of origin and disease status (Taylor and Gercel-Taylor, 2008; 
Jia et al., 2014). Notably, exosomes have been isolated from numerous biofluids, including 
serum, plasma, cerebrospinal fluid (CSF), urine, and saliva and utilized for biomarker 
discovery, monitoring of therapy, as well as potential platforms for personalized medicine 
(Zocco et al., 2014; Verma et al., 2015; Ogawa et al., 2008; Pisitkun et al., 2004; Street et 
al., 2012).  
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1.1 Classification and biogenesis 
The terminology referring to exosomes and EVs has changed tremendously over the past 
decade, with the words “exosomes”, “microvesicles”, and “microparticles” used 
interchangeably in the literature (Momen-Heravi et al., 2013; van der Pol et al., 2012). Since 
the current understanding of EV biogenesis is incomplete, EV isolation protocols and vesicle 
characterization varies, this terminology is used interchangeably in this thesis. 
 
The heterogeneous family of EVs that can be broadly classified based on morphological 
characteristics, mode of biogenesis, and molecular markers (Box 1.1) (van der Pol et al., 
2012). Thus, exosomes are the smallest (50-150 nm) and most studied subpopulation of EVs 
derived from multivesicular bodies (MVBs) (Denzer et al., 2000; Barry et al., 1998). These 
particles are understood to arise from early endosomes that can undergo ubiquitin-dependent 
interactions with endosomal sorting complexes required for transport (ESCRT) (ESCRT-0, 
ESCRT-I and ESCRT-II) and be recycled. Alternatively, they can proceed towards a late 
endosomal pathway and initiate exosome biogenesis (Raiborg and Stenmark, 2009). Late 
endosomal pathways are dependent on multivesicular bodies, are ubiquitin-independent 
pathways, and lead to formation and sorting of exosomes (de Gassart et al., 2004). In these 
pathways, ALG-2-interacting protein X (ALIX) can bind directly to the exosomal cargo 
molecules, which differentiate between exosomal sorting pathways and lysosomal recycling 
pathways (Hurley and Odorizzi, 2012). Whilst the ESCRT proteins are clearly required for 
the lysosomal degradation of proteins, the function of ESCRT in formation of exosomes is 
less studied (Urbanelli et al., 2013). Furthermore, the Rab GTPase family regulates fusion 
of late-endosomal MVBs with the plasma membrane and exosome release (Ostrowski et al., 
2010). Specifically, Rab5 and Rab7 regulate endocytic trafficking downstream of MVB 
biogenesis and cargo sequestration whereas Rab27a, Rab27b, and Rab35 control the 
secretion of exosomes (Hurley and Odorizzi, 2012; Ostrowski et al., 2010; Vanlandingham 
and Ceresa, 2009).  
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Box 1.1: Classification of extracellular vesicles 
Historically, EV classification was based on cellular origin. However, EVs can be more 
accurately categorized on the basis of their biogenesis. 
 
Oncosomes: tumor microvesicles that transmit signaling complexes between cells. 
Ectosomes: vesicles secreted by human polymorphonuclear leukocytes 
Microparticles: vesicles originated from platelets 
Dexosomes: vesicles released from dendritic cells 
Texosomes: vesicles derived from tumor cells 
 
EV classification based on mode of biogenesis 
 
 
*ESCRT: Endosomal sorting complex required for transport complex, MFGE8: milk fat 
globule-EGF factor 8 protein, TSG101: tumor susceptibility gene 101, HSPs: heat shock 
proteins 
 
Microvesicles (also called shedding microvesicles, shedding vesicles, or microparticles) are 
approximately 100-1000 nm in diameter and originate from the outward budding of the 
plasma membrane (Momen-Heravi et al., 2013). Tumor susceptibility gene 101 protein 
(TSG101), which is also involved in exosomes biogenesis, interacts with arrestin domain-
containing protein 1 (ARRDC1) in the stage of microvesicle budding (Nabhan et al., 2012). 
This protein interaction leads to relocation of TSG101 from endosomes to the plasma 
membrane and mediates the formation of microvesicles (Nabhan et al., 2012). Both exosome 
and microvesicle release are associated with a specific region of plasma membrane which is 
enriched in cholesterol, lipid rafts, and ceramide (Bianco et al., 2009; Nawaz et al., 2014). 
The small GTP-binding protein ADP-ribosylation factor 6 (ARF6), the Rho signaling 
pathway, actin motors, and the elements of cytoskeleton are involved in the formation of 
microvesicles (D'Souza-Schorey and Chavrier, 2006; Li et al., 2012a; Charras et al., 2006). 
•Origin: budding of inter luminal multivesicular bodies of endosomal pathways 
•Size: 50-150 nm
•Surface markers: Tetraspanins (CD63, CD 81,CD82, CD9), ESCRT components, 
TSG101, Flotillin 1 and Flotillin 2, HSPs, ALIX, MFGE8
Exosomes
•Origin: Outward budding of plasma membrane
•Size: 100-1000 nm
•Surface markers: AnnexinV, Integrins, CD40 ligand
Microvesicles
•Origin: Outward budding of plasma membrane in apoptotic cells
•Size:500-2000 nm
•Surface Markers: AnnexinV, particularly enriched in phosphatidylserin
Apoptotic bodies
INTRODUCTION 
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Apoptotic vesicles are a subpopulation of EVs that range from 100-2000 nm in diameter and 
are generated by the blebbing of the plasma membrane of cells undergoing apoptosis. Larger 
apoptotic vesicles (1000-5000 nm) are referred to as apoptotic bodies and contain 
fragmented nuclei as well as fragmented cytoplasmic organelles (Gyorgy et al., 2011; Buzas 
et al., 2014). Crucially, uptake of apoptotic bodies originating from tumor cells can transfer 
oncogenic contents to the recipient cells and showed tumorigenic activity (Bergsmedh et al., 
2001).  
 
As indicated herein, vesicles originating from different biogenesis pathways can have 
overlapping diameter ranges (Witwer et al., 2013), making particle size a poor approach to 
EV classification. Presently, as understanding of vesicle formation biomechanics improves, 
characterization and classification of EVs is migrating from particle size to mode of origin. 
However, identification of vesicle-specific molecular patterns is expected to expand the 
horizons of vesicle classification in the future.  
 
1.2 Function of extracellular vesicles in physiology and 
pathology 
Increasing evidence suggests that EVs have multiple functions in both physiological and 
pathological conditions. Thus, beyond cell signaling, exosomes can exert immune 
modulation by transporting ligands and receptors (Martinez et al., 2006; Martinez-Lorenzo 
et al., 1999), presenting antigens (van Niel et al., 2001; Van Niel et al., 2003), transferring 
cytokines (Vojtech et al., 2014) and signaling components (Njock et al., 2015), triggering 
inflammation (Bretz et al., 2013), transferring genetic information (Valadi et al., 2007; 
Momen-Heravi et al., 2015a), and contributing to the spread of infectious diseases 
(Narayanan et al., 2013; Bukong et al., 2014). In tumorigenesis, exosomes have been 
demonstrated to trigger cancer cell proliferation, induce angiogenesis, and ultimately 
promote tumor growth and metastasis (Tickner et al., 2014). Table 1.1 provides a summary 
of the key roles of EVs in different pathological conditions. 
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Table 1.1: Role of extracellular vesicles in pathogenesis of different diseases 
Disease Vesicle type Reference 
Infectious disease   
Parasitic trematodes/nematodes: immunomodulation Exosomes (Marcilla et al., 
2012) 
Spongiform encephalopathies: spread of transmissible prions via the 
blood 
Exosomes (Saa et al., 
2014) 
HIV: miRNAs transport involved in HIV-associated neuronal 
dysfunction, trans-infection of CD4+ T-cells 
Exosomes (Hu et al., 
2012),(Wiley 
and 
Gummuluru, 
2006) 
Malaria: Cellular communication within the parasite population/ 
immunomodulation of host innate immune system for parasite 
survival 
Exosomes (Mantel et al., 
2013) 
Epstein–Barr virus: viral biogenesis and egress, exosome-dependent 
immune suppression in EBV-associated lymphomas 
Exosomes (Meckes et al., 
2013), (Pegtel et 
al., 2010) 
Cancer   
Promote thrombosis, cell proliferation, and angiogenesis Exosomes, 
Microvesicles  
(Kucharzewska 
et al., 2013), 
(Webber et al., 
2010), (Liu et 
al., 2015), 
(Millimaggi et 
al., 2007) 
Prepare a tumor friendly environment to accept metastatic niches, 
formation of pre-metastatic niche in different organs 
Exosomes, 
Microvesicles 
(Rana et al., 
2013), (Costa-
Silva et al., 
2015) 
Inducing pro-vascular phenotype by modulating bone marrow  Exosomes (Peinado et al., 
2012) 
Tumor escape from immune system Exosomes, 
Microvesicles 
(Clayton et al., 
2007), (Szajnik 
et al., 2010), 
(Andreola et al., 
2002) 
Metabolic disease   
Diabetes: activate marginal zone–like B cells in NOD mice, an effect 
associated with onset of diabetes 
 
Extracellular 
vesicles 
(Bashratyan et 
al., 2013) 
Insulin resistance in treated adipocytes influenced by pro-
inflammatory macrophages 
Extracellular 
vesicles 
(Zhang et al., 
2015) 
Inflammatory disease    
Rheumatoid arthritis: associated joint inflammation by inducing 
coagulation and contributing to fibrin deposition  
Microvesicles (Berckmans et 
al., 2002) 
 
1.3 Circulating microRNAs and exosome-associated 
miRNAs: regulators of gene expression 
MicroRNAs constitute a class of small non-coding RNAs ranging from 18-25 nucleotides in 
length, produced by RNase III proteins, namely Dicer and Drosha (Ha and Kim, 2014). The 
regulatory role of microRNAs (miRNAs) in different cellular processes and disease 
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pathogenesis has drawn much attention to the potential of miRNAs as biomarkers. Whereas 
some miRNAs regulate specific genes, some miRNAs have master regulatory functions and 
regulate hundreds of targets (He and Hannon, 2004). MicroRNA biogenesis is initiated in 
the nucleus of a cell and finalized in the cytoplasm, where they are loaded onto the so-called 
RNA induced silencing complex (RISC complex). RISC then targets mRNAs usually 
located at their 3’ untranslated region (UTR), resulting in either target mRNA degradation 
or translational repression (Bartel, 2009) (Figure 1.1). Other roles such as the regulation of 
epigenetic changes and target regulation at the 5′ UTR are also attributed to miRNAs (Fabbri 
et al., 2013) and it is estimated that miRNAs regulate the translation of more than 60% of 
protein-coding genes (Esteller, 2011). Extracellularly, biologically active miRNAs can be 
found in two distinct forms: exosome-associated miRNAs and free floating miRNAs, with 
the majority of miRNAs in biofluids  associated with exosomes (Gallo et al., 2012). These 
reports have introduced new opportunities in causal biomarker discovery in exosome-
associated miRNAs. 
 
 
Figure 1.1: MicoRNA biogenesis and function. MicroRNA can originate from apparently 
dedicated non-coding RNA transcripts, coding transcripts and other non-coding sequences, 
including from regions that may normally be subject to translation or alternative splicing. 
Primary miRNAs (pri) are transcribed from the genome by RNA polymerase II/III in the 
nucleus. Pri-miRNAs are cleaved by the Drosha/DGCR8 complex to form precursor (pre) 
miRNAs. Pre-miRNAs are next transported to the cytoplasm via exportin-5. Dicer along 
with TRBP cleaves pre-miRNAs to mature miRNAs, with strand selection taking place at 
this stage. The functional strands form a complex with Ago2 and GW182 and thus constitute 
the RNA-inducing silencing (RISC) complex. Binding onto targets with complete or partial 
complementary induces mRNA cleavage, translational activation or suppression (Roberts, 
2014; Matsui et al., 2013; Moschos, 2013). 
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It is now very well established that a large number of miRNAs play active roles in the 
pathogenesis of disease and are frequently dysregulated in many distinct indications. These 
characteristics enable researchers to use them for diagnostic purposes or as therapeutic 
targets (Heneghan et al., 2010). Interestingly, deep sequencing data showed that miRNAs 
are the most abundant type of RNA in plasma-derived exosomes, corresponding to 76% of 
all mappable reads (Huang et al., 2013). Target gene enrichment analysis and functional 
experimental results suggest that highly abundant exosome-associated miRNAs may have 
important functions in protein phosphorylation, RNA splicing, and the modulation of 
immune functions (Momen-Heravi et al., 2015a; Momen-Heravi et al., 2015b; Huang et al., 
2013). Given these and other effector roles have been attributed to exosomal miRNAs, 
miRNAs constitute the most well studied group of the exosome-associated transcriptome. 
 
1.4 Function of exosomes in liver physiology and 
pathology 
Exosomes derived from cholangiocytes and hepatocytes have been suggested to play a role 
in intercellular communication between hepatocytes, cholangiocytes, and sinusoidal 
endothelial cells (Witek et al., 2009; Masyuk et al., 2010). Thus, biliary exosomes were 
reported to induce a decrease of the phosphorylated-to-total extracellular signal-regulated 
kinase (ERK)1/2 ratio, an increase in miRNA-15A expression levels and a decrease in the 
proliferation of cholangiocytes (Masyuk et al., 2010). Exosomes isolated from hepatitis c 
virus (HCV)-infected human hepatoma Huh 7.5.1 cells were reported to contain a complete 
sequence of viral RNA, functional viral proteins and, importantly, the ability to transmit 
HCV infection to other naïve human hepatoma cells (Ramakrishnaiah et al., 2013; Bukong 
et al., 2014). Exosomes were also reported  to contribute to the antiviral response of 
interferon alpha (IFN-α) to the mouse hepatitis virus strain A59 and adenovirus in an in vivo 
mouse model (Li et al., 2013). Elsewhere, in a hepatocellular carcinoma (HCC) model, co-
culture experiments demonstrated that exosomes derived from HCC cells could induce HCC 
cell growth, migration, and metastasis and deliver miRNAs to the recipient cells (Wei et al., 
2015). 
 
Exosomes isolated from a colorectal cancer cell line (HT-29), which has a substantial 
potential for metastasis, were also shown to significantly promote metastatic tumor 
formation by Caco-2 colorectal cancer cells; thus, whilst Caco-2’s ordinarily exhibit poor 
liver metastatic potential (Wang et al., 2015). Interestingly, the recipient mice also presented 
high levels of C-X-C chemokine receptor type 4 (CXCR4) in the metastatic 
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microenvironment. Thus, these findings were proposed to imply that exosomes may play a 
role in promoting colorectal cancer metastasis, by employing CXCR4-expressing stromal 
cells to develop a susceptible metastatic microenvironment (Wang et al., 2015). This thesis 
is corroborated from evidence derived by other groups on the role of stromal CXCR4 in 
promoting the formation of metastatic niches, angiogenesis, and tumor growth (Guo et al., 
2016; Yang et al., 2015). Similarly, exosomes released from CD90+ cancer cells were 
reported to be enriched in long non-coding RNA (LncRNA) H19, promoted angiogenic 
phenotype and cell-to-cell adhesion in endothelial cells (Conigliaro et al., 2015). 
Additionally, it has been reported that in pancreatic ductal adenocarcinoma (PDAC), PDAC-
derived exosomes promote liver pre-metastatic niche formation in naive mice (Costa-Silva 
et al., 2015). Thus, macrophage migration inhibitory factor (MIF) was highly expressed in 
PDAC-derived exosomes and resulted in recruitment of bone marrow-derived macrophages. 
Moreover, PDAC-derived exosomes were taken up by Kupffer cells (KCs), causing the 
secretion of transforming growth factor β and upregulation of fibronectin production by 
hepatic stellate cells. The resulting inflammatory and fibrotic microenvironment thus was 
interpreted to prime the liver for metastasis (Costa-Silva et al., 2015). Elsewhere, exosomes 
secreted from motile HCC cell lines enhanced the migratory and invasive abilities of MIHA 
cells (an immortalized, non-tumorigenic, normal human hepatocyte cell line), activating the 
phosphoinositide 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) 
signaling pathways (He et al., 2015). HCC tumor-derived exosomes were also shown to 
contain a special miRNA signature, which appears to modulate identified transforming 
growth factor β activated kinase-1 (TAK1) pathways and enhance transformed cell growth 
in recipient cells, further promoting hepatocarcinogenesis (Kogure et al., 2011). Hepatocyte-
derived exosomes were also shown to possess a regenerative capacity by delivering the 
synthetic machinery to form sphingosine 1 phosphate (S1P) in target primary hepatocytes, 
leading to an increase in cell proliferation and liver regeneration after ischemia/reperfusion 
injury or partial hepatectomy (Nojima et al., 2016). Interestingly, the function of liver cell 
derived exosomes appears to extend into metabolism. Thus, repeated injections of exosomes 
isolated from the peripheral blood of mice fed a high-fat diet to mice on a regular diet, 
resulted in aggregation of activated immature myeloid, CD11b+Ly6ChiLy6G− cells in the 
liver. This was accompanied by chronic inflammation characterized by an increase in serum 
interleukin 6 (IL-6), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) 
and the promotion of fatty liver disease (Deng et al., 2009). From a clinical perspective, 
circulating exosomes in patients with primary biliary cirrhosis, an autoimmune liver disease, 
were also shown to significantly change co-stimulatory molecule expression on antigen-
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presenting populations in an ex vivo disease model (Tomiyama et al., 2015). Figure 1.2 
summarizes exosome biogenesis and the role of exosomes in liver physiology and pathology.  
 
 
Figure 1.2: Exosome biogenesis and role of EVs in different liver pathologies 
 
1.5 Exosomes/EVs as biomarkers of disease 
The National Institutes of Health define biomarkers as “A characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention”(Biomarkers Definitions Working, 
2001). “Liquid biopsy” represents an emerging novel approach in biomarker discovery for 
diagnostics, monitoring and evaluation of prognosis, as well as treatment outcomes in 
various diseases (Jia et al., 2014; Crowley et al., 2013), and refers to the collection of biofluid 
samples that contain biomarkers of disease, typically neoplastic. Comprehensive profiling 
of cells and biofluids using proteomic, genomic, and transcriptomic analysis has resulted in 
a paradigm shift on the understanding of disease pathogenesis mechanisms, the possibility 
of early diagnosis and the monitoring of prognosis. Accordingly, EVs can be purified from 
readily available biofluids, both invasive and non-invasive, such as serum, plasma, urine, 
CSF and saliva. The fact that exosomes are natural carriers of biomolecules that improve 
their biological stability, as well as the emerging understanding of their pivotal, often causal 
roles in the development and progression of disease, positioned them as promising substrates 
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for the discovery of clinically relevant diagnostic and prognostic biomarkers. Thus, the 
gamut of relevance has thus been shown to include multiple cancers, autoimmune disease, 
metabolic disorders, infectious disease, and other systemic pathologies (Kalani et al., 2014; 
San Lucas et al., 2015; Sadovska et al., 2015), opening up new perspectives in the field of 
liquid biopsy diagnostics.  
 
Beyond the general increase in EV concentrations under pathological conditions the 
encapsulated proteins, lipids and nucleic acids have been reported by multiple groups to 
inform disease status (Akers et al., 2013; Turchinovich et al., 2011; Galindo-Hernandez et 
al., 2013), even with mechanistic roles in pathogenesis (Candelario and Steindler, 2014; 
Bergsmedh et al., 2001; Buzas et al., 2014). Crucially, these roles can establish discovery of 
causal biomarkers instead of simply correlational biomarkers. Secondly, by focusing 
analytics onto the exosome fraction, the complexity of biofluids can be reduced, thereby 
diminishing data noise and increasing signal levels, i.e. facilitating the detection of less 
abundant biomarkers (Boukouris and Mathivanan, 2015; Willis and Lord, 2015; Momen-
Heravi et al., 2015b) - a phenomenon described as “less being more”. Thus, subsets of low 
abundance biomarkers in biofluids can be highly enriched in the exosomal sorting process 
(Properzi et al., 2013). For example, aquaporin protein families, which are key players and 
indicators of renal ischemia/reperfusion injury, have been recovered from exosomes isolated 
from urine; in stark contrast, they are poorly detectable in complete urine (Takata et al., 
2008; Properzi et al., 2013; Sonoda et al., 2009). Thirdly, the lipid bilayer of the exosome 
protects nucleic acids and proteins from RNases, proteinases, DNases, and other enzymatic 
activity present in the biofluids, thereby extending analyte stability (Willis and Lord, 2015; 
Momen-Heravi et al., 2014a; Racicot et al., 2012). Fourthly, exosomes themselves are very 
stable and can perfectly survive different storage conditions (e.g. -20 °C, -80 °C) over 
periods of at least 3 months (Kalra et al., 2013). Thus, in a multiplex study on ovarian cancer 
patients which identified eight miRNAs for discrimination of ovarian cancer from benign 
ovarian disease, miRNA levels were not affected by pre-analytical variables such as storage 
time and collection (Taylor and Gercel-Taylor, 2008). Similar miRNA profiles were 
reported in serum samples stored for a short time at 4 °C (up to 96 h) and when the serum 
samples were kept at -70°C for 28 days (Taylor and Gercel-Taylor, 2008). Fifthly, different 
studies have reported increased sensitivity for exosome-based biomarkers compared to 
whole serum and urine biomarkers (Ogata-Kawata et al., 2014; Logozzi et al., 2009; 
Madhavan et al., 2015). For instance, miRNAs found in exosomes isolated from sera of 
patients with colorectal cancers, showed higher sensitivity (90.0 %) compared to serum 
carcinoembryonic Antigen (CEA) and cancer antigen 19-9 (CA19-9) (30.7 and 16.0% 
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respectively) (Ogata-Kawata et al., 2014). Similarly, higher levels of disease-specific 
biomarkers were reported by others in the exosome fraction of biofluids compared to the 
exosome-depleted fraction (Madhavan et al., 2015; Bala et al., 2012). For example, levels of 
miRNA-4644, miRNA-3976, miRNA-1246, and miRNA-4306 were significantly elevated 
in pancreatic cancer exosomes compared to controls, while these miRNAs were only slightly 
elevated in exosome-depleted serum of patients with pancreatic cancer (Madhavan et al., 
2015). In line with these reports, in alcoholic hepatitis and inflammatory liver injury, 
miRNA-122 and miRNA-155 were predominantly found in the exosome fractions of 
plasma/serum, as opposed to the exosome-depleted fractions (Bala et al., 2012). 
 
1.6 Exosomes as biomarkers of liver diseases: 
challenges and opportunities 
As sedentary lifestyles and dietary changes become more common, the health burden of liver 
diseases is increasing (Nseir et al., 2014). Unfortunately, the silent nature of liver disease 
progression and the absence of symptoms until late phases pose challenges to timely 
diagnosis. Given the invasiveness and risk associated of liver biopsy, exploration of 
minimally invasive liver diagnostic methods has attracted considerable attention (Aithal et 
al., 2012). Importantly, the outcomes of a diverse set of liver diseases including alcoholic 
hepatitis, steatosis, viral and bacterial hepatitis, liver autoimmune disease and fibrosis are 
understood to potentially benefit from early diagnosis (Aithal et al., 2012). Traditionally, 
liver biopsy has been considered the gold standard for assessing accurately liver injury 
across various liver pathologies. In lieu of this approach, the extent of liver injury has been 
correlated to the levels of hepatic enzymes in blood, usually alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), and alkaline phosphatase (ALP)/gamma-glutamyl 
transpeptidase (GGT). Nevertheless, serum hepatic enzyme activities lack both sensitivity 
and specificity (Gallo et al., 2012). Moreover, the levels of these biomarkers do not always 
properly reflect the stage of liver disease and extent of hepatocellular injury and can poorly 
discriminate between transient (e.g. dietary) vs established insults (Kim et al., 2008). 
However, recent findings have presented various novel liquid biopsy biomarkers as suitable, 
minimally invasive alternatives (Mohankumar and Patel, 2015). Thus, with the introduction 
of systems-wide analytical methodologies, commonly referred to as “Omic technologies”, 
the proteome, transcriptome, lipidome, and metabolome have been explored for their 
biomarker potential.  
 
Increased levels of various subpopulations of circulating exosomes have been reported in 
patients with hepatitis C and acute liver failure, compared to healthy subjects (Brodsky et 
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al., 2008; Agarwal et al., 2012). Full-length soluble protein tyrosine phosphatase γ 
(sPTPRG) isoforms associated with exosomes have been reported to be well-correlated with 
different stages of liver injury (Moratti et al., 2015). Soluble CD81 was identified to be 
increased in exosomes isolated from sera in patients with chronic hepatitis C compared to 
patients with cured hepatitis and healthy individuals (Welker et al., 2012). Elsewhere, using 
affinity immune isolation, circulating exosomes enriched in liver-origin protein Hepatocyte 
paraffin 1 (Hep par 1) isolated from plasma of hepatocellular carcinoma patients (Brodsky 
et al., 2008) were positively correlated with  liver tumor size (Brodsky et al., 2008). In 
addition to CD81, a panel of exosomes isolated from urine of acute liver injury animal 
models contained differentially expressed proteins including CD26, solute carrier family 3 
member 1 (Slc3A1), and CD10 and were suggested as biomarkers of liver disease in acute 
liver injury animal models (Conde-Vancells et al., 2010). 
 
High-throughput plasma exosome-associated miRNA profiling showed that nine miRNAs 
(miRNA-1225-5p, miRNA-1275, miRNA-638, miRNA-762, miRNA-320c, miRNA-451, 
miRNA-1974, miRNA-1207-5p, and miRNA-1246) were differentially expressed in 
patients with chronic hepatitis C and controls which allowed categorizing subjects as chronic 
hepatitis C patients or healthy controls with 96.59% accuracy (Murakami et al., 2012). 
Similarly, exosome-associated miRNA-18a, miRNA-221, miRNA-222 and miRNA-224 
recovered from serum exosomes were significantly elevated in patients with HCC compared 
to patients with chronic hepatitis B or liver cirrhosis. Importantly, the whole serum levels of 
circulating miRNAs showed less sensitivity and specificity for detection of HCC compared 
to the exosome-associated miRNA fraction (Sohn et al., 2015), justifying the diagnostic 
value of exosome-specific analysis. Similarly, miRNA-21 was significantly higher in 
exosomes isolated from sera of patients with HCC; the improved discriminatory power and 
diagnostic accuracy compared to miRNA-21 measurement in the exosome-depleted serum 
fraction highlighted the exosomal origin of this biomarker. Interestingly, levels of exosome-
associated miRNA-21 were higher in patients with liver cirrhosis which is the primary risk 
factor for developing HCC, and high grade tumor stage (Wang et al., 2014).  On the other 
hand, decreased levels of miRNA-718 were associated with HCC re-occurrence after liver 
transplant and tumor aggressiveness in different cohorts of patients (Sugimachi et al., 2015). 
Importantly, although exosome-associated miRNAs showed interesting results for 
biomarker studies, this area of research is still in the descriptive phase and the results are not 
validated in large independent cohort studies. 
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Although EVs have been successfully isolated from multiple biofluids, including plasma 
(Caby et al., 2005), serum (Chen et al., 2013), urine (Raj et al., 2012), saliva (Sivadasan et 
al., 2015), amniotic fluid (Asea et al., 2008), and breast milk (Lasser et al., 2011), there are 
considerable inconsistencies in the isolation methods employed. Several established 
methods were introduced and utilized for the isolation and purification of exosomes, 
including ultracentrifugation, antibody-coated magnetic beads, microfluidic devices, 
polymeric precipitation technologies, size exclusion methods, sieving, porous nano-
structures, as well as emerging technologies. Although each method features advantages and 
disadvantages, it is important to note that none have shown superiority for all purposes and 
comparative efficacy studies are limited to only a handful of diagnostic scenarios. In fact, 
the method of isolation has been demonstrated to directly affect the reproducibility and 
reliability of all downstream analyses: any uncertainty and errors in the isolation procedure 
may also irreversibly change outcomes, conclusions and ultimately the validity of any 
obtained results (Witwer et al., 2013). Thus, presently none of the reported methods has 
dominant superiority for all diagnostic purposes and method selection can be based on the 
type of biofluid, EV target sub-population, clinical setting, or a combination of methods. In 
spite of the fact that most approaches rely upon a high level of purity, the selection of one 
method over another in the clinical setting is greatly dependent on the goal in mind. As with 
other biological products, purity, concentration, yield, and selective isolation in a rapid and 
cost effective manner remain the principal goals. However, preferential aim tradeoffs should 
be made depending on the circumstances, in order to maximize overall effectiveness. 
 
In spite of the emerging understanding of the mechanistic role and diagnostic value of EVs, 
important limitations continue to exist in conducting exosome-based biomarker discovery. 
The most important challenges are pre-analytical, problems in reproducibility, and obstacles 
in characterization and isolation methods (Momen-Heravi et al., 2013; Witwer et al., 2013). 
Currently, the lack of a standardized protocol for isolation hinders translation into the clinical 
setting. Validation studies supporting transition from discovery to diagnostic use require the 
development of standardized, reproducible and quantifiable isolation and characterization 
methods (Momen-Heravi et al., 2013; Witwer et al., 2013; Jia et al., 2014; Momen-Heravi 
et al., 2012a) as well as the establishment of appropriate normative controls (Witwer et al., 
2013).  
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1.7 MicroRNA-targeted gene therapy and conventional 
gene delivery vehicles 
Notwithstanding the diagnostic and potentially causal value of EV microRNAs, these 
biomolecules are established regulators of physiology, pathogenesis and disease. Therefore, 
correcting miRNA deregulation by miRNA mimics and inhibitors seems as an attractive 
method to control aberrant cell functions. Therapeutic oligonucleotides in their so-called 
naked (i.e. unformulated) forms are very difficult to deliver due to chemical instability, 
susceptibility to RNases and lack of controlled distribution to relevant tissues and cells 
(Takakura et al., 2001; Soutschek et al., 2004; Min et al., 2010). Gene delivery vehicles 
(GDVs) including viral vectors and cationic liposomes were introduced to overcome these 
limitations (Gehrig et al., 2014; Awada et al., 2014). Suitable viral vectors can be found 
amongst adeno-associated viruses (AAV), adenoviruses, herpes viruses and lentiviral 
vectors (Serguera and Bemelmans, 2014). However, all of these can induce moderate to 
severe immune response against both vehicles and transgenes. Although among viral vectors 
AAVs induce milder immune reactions and limited cellular response, AAVs can induce 
humoral responses and the formation of AAV neutralizing antibodies, which can obstruct 
efficacy (Xiao et al., 1996; Masat et al., 2013). Moreover, capsid-specific T cell responses 
directed toward transduced cells can result in short-lived transgene expression due to 
clearance of transduced cells (Masat et al., 2013).  Additional risks include genomic 
integration, immune-related diminished efficacy over repeated administration, high rate of 
insertional mutagenesis, and lack of ability to transfer large RNA-based cargos. Amongst 
non-viral, synthetic systems, cationic liposomes are mostly cytotoxic and immunogenic 
(Zhang et al., 2005), have low transfection efficacy and can be quickly cleared from the 
circulation (Seow and Wood, 2009; Awada et al., 2014). Use of immune ‘stealth’ and renal 
clearance control approaches (e.g. poly-ethylene glycol) further diminishes transfection 
efficiency, unless the system is upgraded with appropriate receptor targeting ligands- at 
significant cost-of-goods, chemistry and manufacturing controls (CMC) expense 
(Nicolaides et al., 2010). 
 
In some cases, the simultaneous use of immunosuppressive agents is also recommended to 
prevent adverse immune response and increase cellular uptake (Jiang et al., 2006; Wang et 
al., 2007). For example, in rhesus macaques, a regimen consisting of Mycophenolate mofetil 
(MMF) and tacrolimus administered before and after adeno-associated virus serotype 8 
(AAV8) vector expressing human factor IX hFIX (AAV8-hFIX) was safe and lead to higher 
transduction efficacy (Jiang et al., 2006). Similarly, Bortezomib decreased anti-AAV titers 
up to 10 fold in mice after vector administration (Karman et al., 2012). Administration of a 
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non-depleting anti-CD4 antibody targeting CD4+ T helper at the time of vector delivery was 
also reported to attenuate the antibody responses to AAV vectors (McIntosh et al., 2012). 
Liposomal small interfering RNA (siRNA) delivery vehicle induced inflammatory response 
was inhibited by the glucocorticoid receptor agonist dexamethasone, without reducing 
siRNA efficacy (Abrams et al., 2010). Thus, it would appear that the immune-activation 
properties of both viral vectors and synthetic delivery systems necessitate the use of 
concomitant immunosuppressive strategies to enhance uptake and reduce the adverse 
immune responses, which complicates drug formulation and reduces administration 
opportunities (Masat et al., 2013). 
 
Bacteriophages are another class of GDVs which have exhibited good safety and stability 
(Jepson and March, 2004). However, their clinical use in gene therapy applications is limited 
due to the robust antibody responses and rapid elimination by the reticuloendothelial system 
(RES) (Molenaar et al., 2002; Bakhshinejad and Sadeghizadeh, 2014).  The substantial 
hazards of traditional GDVs has limited their applications to cases which benefits highly 
outperform hazards. Presently, there are only two gene therapy products whose clinical use 
has been approved by European regulators, Alipogene tiparvovec (Glybera®; uniQure 
biopharma B.V, Amsterdam, NL) and Strimvelis (GSK2696273; GlaxoSmithKline, 
Brentford, UK). Alipogene tiparvovec is a gene therapy product for the treatment of 
lipoprotein lipase deficiency (LPLD), a rare autosomal recessive disorder is caused by 
mutation in the genes codes lipoprotein lipase (LPL) (Gaudet et al., 2016). Glybera consists 
of a LPL gain-of-function allele delivered by an AAV vector. Clinical data showed efficacy 
of the drug in expression of LPL-protein in injected muscles and a diminished incidence and 
severity of pancreatitis attacks up to 6 years post-treatment (Gaudet et al., 2016). As a result, 
the European Medicines Authority approved Glybera for adult familial LPLD patients. 
However, the incidence is very low (1 in 1,000,000) and the price for treatment is presently 
over 1 million US dollars. Strimvelis has been recently approved for the treatment of severe 
combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) in 
patients who cannot undergo a bone-marrow transplant due to the lack of a suitable, matched 
donor. The incidence of ADA-SCID is <9 out of every 1,000,000 live births. The drug 
consists of an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced 
with retroviral vector (LXSN vector), encoding the human adenosine deaminase (ADA) 
complementary DNA (cDNA) sequence, thereby replacing defective ADA in immune cells; 
long term follow up (median 4 years) showed 100 % survival rate (Hoggatt, 2016; Cicalese 
et al., 2016). The price for a treatment is over 600,000 US dollars, with the manufacturer 
offering a full treatment cost refund in case of lack of efficacy. Altogether, high prices, 
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limited markets, public perceptions over gene therapy, lack of long term human safety 
studies, regulatory issues, and possible immunogenicity are limiting factors in the extension 
of gene therapy (Narayanan et al., 2014) and its application beyond orphan disease. In this 
context, exosomes have attracted attention as alternative drug delivery vehicles. Key among 
the reasons for evaluating EVs are their long circulating half-life, lower manufacturing cost, 
intrinsic ability to target tissues, biocompatibility, minimal or no immunogenicity even with 
repeated administration, and no inherent toxicity reported thus far  (Ha et al., 2016; Turturici 
et al., 2014; Marcus and Leonard, 2013). 
 
1.8 MicroRNA-targeted therapy using exosomes as 
delivery vehicles 
Given miRNA are naturally found in exosomes, this EV subset has attracted considerable 
attention in the scientific community as a putative solution for RNA interference (RNAi) 
delivery. Indeed, the natural ability of exosomes to deliver different endogenous nucleic 
acids is well documented (Valadi et al., 2007; Deregibus et al., 2007). For instance, it has 
been shown that EVs derived from endothelial progenitor cells can deliver miRNA to human 
microvascular and macrovascular endothelial cells and activate the PI3K-AKT signaling 
pathway (Deregibus et al., 2007). Valadi et al., 2007, showed that human mast cell derived 
exosomes can deliver mRNA to murine mast cells and those mRNAs were translated (Valadi 
et al., 2007). Notably, it has been found that EVs contain several key proteins and ribonucleic 
acids involved in RNA processing and RNA transport including GW182, Argonate 2 (AGO 
2), double-stranded RNA-binding protein Staufen homolog 1(STAU1), and Staufen 
homolog 1 (STAU2), suggesting that RNA delivery is dynamically controlled and 
evolutionary evolved in exosome biology (Collino et al., 2010; Gibbings et al., 2009; Zhang 
et al., 2010). All these findings help to position exosomes as highly suitable candidates for 
drug delivery, particularly nucleic-acid based delivery.  
 
Although exosomes are generally nanoparticulate structures with monodisperse size 
distribution sometimes similar to phage, viruses and synthetic GDVs, they exhibit key 
advantages in terms of stability, distribution, targeting, efficacy, metabolism and 
elimination. Unlike the limited compositions of synthetic GDV, exosomal lipid bilayers 
contain cholesterol, sphingomyelins, glycerophospholipids with long and saturated fatty acyl 
chains and desaturated molecular species such as phosphatidylethanolamines. This rigid 
lipid composition decreases the uptake of exosomes by macrophages in vitro and may also 
underpin RES cellular uptake (Laulagnier et al., 2004; Allen et al., 1991). In contrast, 
bacteriophages exhibit a rapid clearance by the RES (Drulis-Kawa et al., 2012).  
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Notably, one of the great benefits of exosomes as biological GDVs appears to be their high 
efficacy in delivering nucleic acids without inducing adverse immune reactions (Banizs et 
al., 2014), the biggest challenge of viral systems. Thus, early studies in mice indicated that 
repeated intra-venous administration of autologous exosomes isolated from dendritic cells 
did not result in any immune activation or maturation of splenic dendritic cells (Wahlgren 
et al., 2012; Morelli et al., 2004).  
 
Importantly, there are also some reports regarding the immune tolerance of EVs even 
between species.  For example, exosomes derived from human mesenchymal stem cells were 
reported both as well-tolerated and functional in immune-competent mice (Arslan et al., 
2013). In another report, EVs derived from human embryonic kidney 293 (HEK293) cells 
were also well-tolerated and functional in T cell deficient (RAG2−/−) mice, successfully 
delivering let-7a miRNA to epidermal growth factor receptor (EGFR)-expressing breast 
cancer xenografts (Ohno et al., 2013).  
 
Crucially, the capacity of EVs to deliver nucleic acids is not restricted to biologically 
generated compounds. Thus, exogenous nucleic acids (e.g. synthetic, fluorescently tagged 
miRNA-150 oligonucleotide mimic) were transfected into human monocytic THP-1cells, 
and recovered from EVs isolated from the transfected THP-1 cell culture medium. 
Moreover, these EVs were able to transfer miRNA-150 to dermal microvascular 
endothelium (HMEC-1) cells, which had very low level of miRNA-150 initially, and reduce 
the levels of the miRNA-150 target, c-Myb to strongly increase HMEC-1 cell migration 
across transwell filters up to 2.5 fold (Zhang et al., 2010). In a murine Alzheimer’s disease 
model, synthetic siRNA was delivered via exosomes to the brain, outperforming 
conventional siRNA-transfection reagent complexes (Altogen Biosystems, Las Vegas, NV, 
USA) in crossing blood brain barrier (Alvarez-Erviti et al., 2011). Whilst injection of siRNA 
transfection reagent complexes failed to decrease β-secratase1 protein mRNA levels and 
associated protein expression, intravenously injected, targeted exosomes derived from 
autogenous dendritic cells efficiently delivered siRNA, specifically to cortical section of 
brain and led to a 62% knockdown of β-secratase1 protein, a therapeutic target in 
Alzheimer's disease (Alvarez-Erviti et al., 2011). Wahlgren et al., 2012 showed that siRNAs 
can be loaded into human plasma exosomes via electroporation and those exosomes can be 
internalized by human monocytes (Wahlgren et al., 2012). Crucially, the electroporetically 
encapsulated siRNA also appeared effective within the transduced monocytes and induced 
knockdown of the targeted proteins. 
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Although recent studies have opened new horizons in the use of exosome-based delivery 
methods for targeting different pathways, there are several challenges that have to be 
addressed before clinical use of exosomes can be pursued. Firstly,  to produce clinical grade 
exosome preparations, isolation techniques should be standardized and reproducible with 
sterility assurance (Witwer et al., 2013) as a minimum, in line with the CMCs applied to 
other biologics and in context with manufacturing standards for non-viral 
nano/microparticulate drug delivery systems. Thus, exosome products should be 
characterized in terms of size, surface markers, aggregation risk/potential, and cargo profile 
as well as presence of isolation-related impurities such as polymer or beads and cell culture 
media components.  Secondly, given exosome contents are different based on the parental 
cell type and status (Jia et al., 2014), the choice of exosome type for delivery is expected to 
be crucial and should be based on the content of the exosomes, target macromolecules, and 
the type of donor and recipient cells. Thirdly, although clinical and animal studies have 
revealed that autologous exosomes are well-tolerated even after repeated administration 
(Escudier et al., 2005), the long-term clinical safety, particularly in heterologous transfer and 
in the context of latent infection, given the transmissibility of HCV via exosomes, should be 
determined.  
 
1.9 Aim and scope of this thesis 
Understanding the function of EVs and miRNAs and their role in pathogenesis is a very 
active line of research. A search in the PubMed database for the terms exosomes OR 
microvesicles OR extracellular vesicles yielded more than 12200 indexed articles in July 
2016.  However, the work conducted thus far is still in the descriptive phase and hampered 
by challenges in isolation and analytical methods, as well as our precise understanding of 
the role of exosomes/EVs in disease biogenesis. Using miRNA-based targeted therapy and 
utilizing exosomes for nucleic-acid based drug delivery is another attractive approach for 
disease treatment. However, the potential for success is balanced by a substantial need for 
development, standardization, and tailoring based on the disease in question, if not the 
molecular pathways dysregulated in specific patient cohorts. This research aimed to establish 
and compare methods for isolation and characterization of exosomes and explore the 
functional role of exosomes and exosomal miRNAs in the pathogenesis of different diseases 
including alcoholic hepatitis, hepatitis C, and head and neck cancer. The resulting outputs 
have broadened the scope and methods for using EVs and miRNAs for diagnostic purposes 
in these indications. My research has led to a clearer understanding of the bio-distribution of 
exosomes and their encapsulated miRNAs in vivo and in vitro, as well as the establishment 
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of a workflow for harnessing the delivery potential of exosomes to pursue miRNA/RNA 
targeted therapies in both in vitro and in vivo models. 
 
 34 
  
Materials and Methods 
2.1 General methods 
2.1.1 RNA isolation  
Total RNA was extracted using a Direct-zol™ RNA MiniPrep isolation kit (Zymo Research 
Corp, Irvine, CA) or RNeasy mini kit (Qiagen, Germantown, MD). Isolated exosomes from 
blood (150 µl) or culture supernatant (500 µl) were lysed in 500-1,000 µl of QIAzol Lysis 
reagent, based on the pellet size and number of exosomes measured by Nanoparticle 
Tracking Analysis (Nanosight, Malvern, Worcestershire, UK) as described in section 
2.1.6.1. The standard manufacturers’ protocols were followed, and extracted RNA was 
eluted in 25 μl of RNase-free water (Thermo Fisher Scientific, Waltham, MA) for 
downstream analysis. The RNA was quantified using NanoDrop 1000 (Thermo Fisher 
Scientific). Isolated RNA was profiled using an Agilent Bioanalyzer 2100 (Agilent 
technologies, Santa Clara, CA) with a Small RNA Chip for exosomal RNA. For saliva 
samples, total RNA was extracted by RNeasy kit (Qiagen) from 440 µl of saliva, according 
to the manufacturer’s protocol. A NanoDrop spectrophotometer (Thermo Fisher Scientific) 
and a 2100 Bioanalyzer (Agilent Technologies) were used for assessment of RNA quantity 
and quality. 
 
2.1.2 MicroRNA analysis 
TaqMan® miRNA Assays (Applied Biosystems, Foster City, CA) were used for the 
detection and relative expression quantification of different miRNAs, according to 
manufacturer’s protocol, as described elsewhere in detail (Momen-Heravi et al., 2014a). 
Reverse transcription (30 min, 16 °C; 30 min, 42 °C; 5 min 85 °C) was performed using a 
TaqMan stem loop primer, 10 ng RNA, TaqMan primers and a miRNA reverse transcription 
kit (Applied Biosystems) in an Eppendorf Realplex Mastercycler (Eppendorf, Westbury, 
NY). 5µl cDNA was mixed with 5µl TaqMan Universal PCR Master mix (Applied 
Biosystems) and quantitative real-time PCR performed using a Bio-Rad CFX96 iCycler. In 
primary human hepatocytes, and hepatoma cells, RNU-48 was used as internal normalizer 
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as recommended by the manufacturer, after systematic assessment of RNA stability in 
different human tissues and cell lines and amenability to the miRNA assay design. The small 
RNA marker small nucleolar RNA MBII-202 (snoRNA202) was used to normalize the Ct 
value in RAW 264.7 macrophages, mouse hepatocytes, liver mononuclear cells, and KCs as 
recommended by manufacturer for murine samples. In experiments involving miRNA 
analysis of exosomes, synthetic C. elegans (cel)-miRNA-39 (5 µl of a 5 fmol/μL stock tube) 
was spiked during the total RNA isolation process and used to normalize the qPCR data as 
an endogenous control. Where indicated, NormFinder was used to identify the suitable 
endogenous normalizer (Andersen et al., 2004). TaqMan® Pri-miRNA Assays were done 
using FAM dye- labeled TaqMan with glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as an internal control (Barber et al., 2005). For each sample, two independent 
reverse transcription reactions were generated, and each experiment was done in triplicate. 
miRNA Ct values were normalized, and the relative expression levels of specific miRNA 
were presented in accordance with the 2–ΔΔCt method (Livak and Schmittgen, 2001). The 
amplification efficiency of qPCR was verified previously at 99.9 % (Ruijter et al., 2009). 
 
2.1.3 Quantitative real-time polymerase chain reaction (qPCR) for 
coding RNA targets 
For mRNA analyses, 1 μg of total RNA was used to transcribe cDNA using an iScript™ 
cDNA synthesis kit (Bio-Rad Laboratories). 5x iScript reaction mix (4 µl) and iScript reverse 
transcriptase (1 µl) were used with a final volume per reaction of 20 µl. Complete reaction 
mix was incubated for 5 min at 25 ºC, 30 min at 42 ºC, 5 min at 85 ºC and held at 4 ºC. Final 
PCR mixture contained 2.5 μl each of forward and reverse primers, 7.5 μl of 2× SYBR PCR 
mix (Applied Biosystems), and 4 μl of sample. PCR was performed in a Bio-Rad CFX96 
Real-time PCR Detection system (Bio-Rad Laboratories) applying universal cycling 
conditions (2 min at 50 °C, 10 min at 95 °C, 40 cycles of 15 s at 95 °C, and 1 min at 60 °C). 
Cycle threshold (CT) values were determined by automated threshold analysis with CFX 
manager software (Bio-Rad Laboratories). The primer sequences are provided in 
Supplementary table 1. mRNA levels were normalized based on 18S RNA levels (Suzuki et 
al., 2000), and relative expressions were calculated using the 2–ΔΔCt method. 
 
2.1.4 Statistical analysis 
Based on the data distribution, one-way analysis of variance (ANOVA) or a Kruskal-Wallis 
nonparametric test was used to assess differential gene expression levels. Student’s t tests or 
Mann-Whitney U tests were performed for pair-wise comparisons in accordance with the 
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underlying distribution. Data were presented as mean ± standard error of mean (SEM) or 
mean ± standard deviation as indicated. In experiments aimed at biomarker discovery, the 
ability of a specific biomarker to discriminate between patients and control groups was 
evaluated by constructing the receiver operating characteristic curve: the measure of test 
accuracy combining sensitivity and specificity, the area under the curve (AUC), was 
calculated (Metz, 1978; Hajian-Tilaki, 2013). For establishing correlations, a Pearson 
correlation test was used. For statistical analyses, GraphPad Prism v.4.03 (GraphPad 
Software Inc.), SPSS 14.0 (SPSS Inc., Chicago, IL), and nSolver™ Analysis Software were 
used. P values ≤ 0.05 were considered statistically significant,  with false discovery rates 
controlled at 5% by Benjamini–Hochberg (Benjamini and Hochberg, 1995) where relevant.  
 
2.1.5 Western blot 
An established laboratory protocol was used for western blotting. Briefly, proteins were 
extracted using RIPA buffer (Thermo Fisher Scientific) and run on 10 % w/v SDS-PAGE 
gels. Proteins were transferred onto the nitrocellulose membrane  (0.2 µm pore–size) (Bio-
Rad Laboratories). Prior to transfer, the gel was placed in transfer buffer for 15 min and 
transfer sandwich assembled and placed in the cassette (Bio-Rad Laboratories). Transfer was 
performed overnight at 4 °C at a constant current of 10mA. Following transfer, membrane 
was blocked for 1 h in Tris-buffered saline (TBS) buffer (Sigma-Aldrich) supplemented with 
5 % w/v non-fat dry milk and 0.1 % v/v Tween-20 (TBST) (Abcam, Cambridge, MA). The 
blot was incubated overnight with the primary antibody of interest (at a final concentration 
of 1 µg/ml) at 4 ºC and then washed with TBST 3 times and incubated for 1 h with 
horseradish peroxidase-conjugated secondary Immunoglobulin G (IgG) based on the 
primary antibody source and protein target (dilution 1: 10,000). A Clarity™ Western ECL 
substrate kit (BioRad) was used to visualize the blot according to the manufacturer’s 
instructions. Briefly, substrate kit components were mixed in a 1:1 ratio. A volume of 8 ml 
of this solution was incubated with the membrane for 5 min. The blot was analyzed using a 
Fujifilm LAS-4000 luminescent image analyzer.  
 
2.1.6 Characterization of EVs 
2.1.6.1 Nanoparticle tracking analysis (NanoSight) 
Nanoparticle tracking analysis (NTA) is a technique that allows the determination of 
concentration and size of EVs suspended in biofluids or tissue culture samples. The system 
uses a laser light scattering technique to determine the size (measured in nanometers) and 
the concentration of EVs (particles per ml) based on Brownian motion (Dragovic et al., 2011; 
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Momen-Heravi et al., 2012a). The velocity of each vesicle is captured with a highly sensitive 
CCD camera and calculated with image processing software. The concentration range of 108 
to 109 particles per ml is reported to be in the linear range of the device. Using a NanoSight 
NS300 system (Malvern, Malvern, UK), size and concentration of EVs were determined in 
different biofluids and tissue culture supernatants. Before running each set of measurement 
experiments, the NanoSight was calibrated with 100 nm polystyrene beads (Thermo 
Scientific) and the samples recorded for 60 s at room temperature. The exact temperature 
was recorded, and kept constant during the measurements, using the instrument’s 
temperature controller. The NTA software processed the video captures and determined the 
size distribution of particles in nanometers and the concentration of the particles in 
particles/ml. Each sample was measured three times.  
 
2.1.6.2 Transmission electron microscopy (TEM)  
TEM sample preparation, exosomes were re-suspended in phosphate-buffered saline (PBS) 
(Thermo Fisher) and transferred to a formvar-coated copper grid (Polysciences, Warrington, 
PA). The samples were allowed to settle for 30 min and washed sequentially with PBS, using 
absorbing paper in between the washing steps. Fixation was done by dropwise addition of 2 
% v/v paraformaldehyde (Sigma-Aldrich) onto parafilm (Cole-Parmer, Chicago, IL) and 
placing the grid on top of the paraformaldehyde drop for 10 min at room temperature. The 
preparation was followed by five 10 µl washes with deionized water (5 megaohm) and 
specimens were contrasted by adding 2 % v/v uranyl acetate (Sigma-Aldrich) for 15-20 min 
at room temperature. Finally, drops of 0.13 % v/v methyl cellulose (Sigma-Aldrich) and 0.4 
% v/v uranyl acetate were added to the samples (Bukong et al., 2014). The samples were 
visualized by a Philips CM10 Electron Microscope (Philips, Amsterdam, The Netherlands) 
located at University of Massachusetts Medical School operating at 60 to 100 Kv.  
 
2.1.6.3 Scanning Electron Microscopy (SEM) 
Huh 7.5 cells were cultured in 12-well plates (Falcon™ Polystyrene Microplates, Thermo 
Fisher) at density of 105. Cells were fixed with 2.5 % glutaraldehyde for 2 h in a Sorensen 
Phosphate buffer (0.1 M, pH 7.4). After fixation, cells were washed with 1 ml of PBS (pH 
7.4) three times for 5 min, and fixed with 1 % w/v Osmium tetroxide in 0.1 M PBS (pH 7.4) 
for 1 h. The samples were next dehydrated by serial washing with 500 µl of increasingly 
concentrated alcohol diluted in water (30 %, 50 %, 75 %, 85 %, 95 %, 100 % v/v). The 
samples were mounted on a specimen stub (TED PELLA, Redding, CA) and sputter coated 
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with gold/palladium (Sigma-Aldrich). The samples were visualized using a MKII FEI 
Quanta 200 FEG MKII scanning electron microscope (FEI Company, The Netherlands). 
 
2.2 Investigating the role of exosomes & miRNA in 
alcoholic liver disease 
2.2.1 In vivo binge alcohol human study 
The study subjects consisted of 11 healthy male individuals with no history of alcoholism or 
alcohol use habits, who were not consuming more than 12 alcoholic drinks per week. In the 
United States a standard alcoholic drink contains approximately 14 g of pure alcohol as 
defined by National Institute on alcohol abuse and alcoholism (Dawson, 2011). The study 
was approved by the Institutional Review Board for the Protection of Human Subjects in 
research at the University of Massachusetts Medical School (Study approval #2381). The 
study was carried out in accordance with the approved institutional guidelines. Written 
informed consent was obtained and samples were de-identified. Alcohol was given to the 
subjects as 2 ml of 40 % v/v vodka per kg body weight in a final total volume of 300 ml 
orange/strawberry juice. The control group took the same volume of orange/strawberry juice 
at the same time points. Blood was collected at baseline and at 0.5 h, 1 h, 2 h, 3 h, 4 h, and 
24 h post-alcohol consumption in serum separating tubes (BD Biosciences, San Jose, CA). 
 
2.2.2 Animal studies 
All animal studies were approved by the Institutional Animal Care and Use Committee of 
the University of Massachusetts Medical School. Six to eight week old female C57BL6/J 
animals were used for chronic alcohol feeding and binge alcohol drinking studies (n = 6 per 
group). For the chronic alcohol consumption model, the animals received 5 % (v/v) ethanol 
(36 % ethanol-derived calories) containing the Lieber-DeCarli diet (EtOH) for 5 weeks and 
control animals received a pair-fed (PF) diet with an identical amount of calories where the 
alcohol-derived calories were replaced with dextran-maltose (Bio-Serv, NJ, USA). The mice 
in the binge alcohol consumption group received 5  g/kg of 50 % (v/v) ethanol diluted in 
water via oral gavage. After 6 h and 12 h binge alcohol consumption, animals were 
euthanized by pentobarbital overdose and cervical dislocation. Blood was collected from the 
animals via cardiac venipuncture and serum was separated from the whole blood by allowing 
the blood to clot in an upright position for 30 min followed by centrifugation for 15 min at 
1500 x g within one hour of collection. The serum was then aspired and stored at -80 °C. 
 
MATERIALS AND METHODS 
39 
2.2.3 Cell culture  
Huh 7.5 cells (passage 11), primary human hepatocytes (maximum number of divisions 69-
80), and RAW 264.7 cells (passage 9) were cultured in Dulbecco’s modified medium 
(DMEM) (Gibco) supplemented with 10 % v/v exosome-depleted fetal bovine serum (FBS) 
(Exo-FBS™, Thermo fisher), and 1 % v/v of 10,000 U/mL penicillin/streptomycin (Thermo 
Fisher). Huh 7.5 cells and RAW 265.7 cells were cultured in 12 well plates at a seeding 
density of 2x105 and 1x105 cells/well respectively. For experiments involving ethanol 
treatment, 25 mM (mmol/L), 50 mM (mmol/L), and 100 mM (mmol/L) of ethanol were 
added to the cells for different durations (24 h, 48 h, and 72 h). THP1 monocytes (passage 
11) were cultured in RPMI media (Gibco) supplemented with 10 % v/v exosome-depleted 
FBS, in a 5 % v/v CO2 atmosphere at 37  °C. For co-culture experiments, exosomes purified 
from Huh 7.5 cells were added to the THP1 cells for 8 h at 50–100 μg/ml concentrations of 
exosomal total protein. This concentration was comparable to the exosomal total protein 
concentration quantified in human samples by Pierce BCA Protein Assay Kit (Thermo 
Fisher). 
 
2.2.4 Exosome isolation 
For exosome isolation from cell culture, cells were cultured in T75 flasks (Sigma-Aldrich) 
at seeding densities of 2.2x106 cells and a total volume of 10 ml culture media. After two 
days, supernatants were centrifuged at 1500 g for 10-15 min to remove cells. This step was 
followed by centrifugation at 10,000 g for 20 min to deplete residual cellular debris. After 
serial filtration (0.8 μm, 0.44 μm and 0.2 μm) of supernatants, the ExoQuick-TC™ (System 
Biosciences) kit was used to precipitate the supernatant following the manufacturer’s 
guidelines. Isolated exosomes were re-suspended in 500 µl PBS. The isolation and 
resuspension volume ratio was 20:1. 
 
In order to isolate exosomes from sera of human subjects and mice, exosomes were isolated 
from 150 μl of sera with ExoQuick reagent (System Biosciences, USA) according to the 
manufacturer’s recommended protocol. The cell culture suspension was transferred to 
micro/ultracentrifuge tubes and THP1 cells pelleted by centrifugation at 500 x g at 4 °C; 
based on the density of exosomes, such particles are unlikely to co-precipitate with the THP1 
monocytes in these separation conditions (Thery et al., 2006). Exosomes would remain in 
the supernatant and would be discarded. In experimental groups which involved 
lipopolysaccharide (LPS) Escherichia coli 0111:B4 ) (Sigma-Aldrich), 10 nM LPS was 
added to the THP1 cells 6 h before the readouts. LPS, derived from Gram-negative bacteria 
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in the intestinal microflora, has been identified as a major factor in the pathogenesis of 
alcoholic hepatitis, affecting various cell types on account of in gut permeability disturbance 
which facilitates systemic access of LPS via portal circulation (Szabo and Bala, 2010).  
 
2.2.5 Confocal microscopy 
Cell culture supernatant exosomes were labeled using a PKH67 green fluorescent cell linker 
kit (Sigma-Aldrich, St Louis, MI). Briefly, a 250 µl PBS suspension containing 108 
exosomes (counted with NTA as described in section 2.1.6.1) was added to 250 µl Diluent 
C. Dye solution was prepared according to the manufacturer’s recommendation by adding 2 
µl of PKH67 dye solution to 500 mL of diluent C. The 500 µl exosome suspension and dye 
solution were mixed by pipetting. Recipient THP1 cells were co-cultured with the labeled 
exosomes in ratio of 1:1 for 6  h and then washed off three times by three times centrifugation 
of cells (500 x g for 15 minutes) in PBS and discarding the supernatant. Cells were fixed 
with 1 mL of 2 % v/v formaldehyde (Sigma-Aldrich) in PBS. Uptake was visualized in fixed 
cells after 8 h using a Leica TCS SP5 II laser scanning confocal microscope (Leica 
Microsystems, Wetzlar, Germany) equipped with Diode 405 nm and Ar lasers for excitations 
at 405 nm and 496 nm respectively. Nuclei were stained with DAPI (blue) (Thermo Fisher). 
Samples were equilibrated with PBS and approximately 250µl of diluted DAPI (300 nM) 
was added to the coverslip covering the cells. The samples were incubated for 5 min and 
then rinsed three times with 500 µl PBS. The samples were mounted with ProLong® Gold 
antifade reagent (Thermo Fisher). Plasma membrane was contrasted and visualized with a 
Nomarski interference mode. Confocal Z stacked images (0.2 μm stack step, 1 μm range) 
were obtained. The Imaris software (Bitplane Scientific Software, Concord, MA) was used 
to construct 3D projections of image stacks. 
 
2.2.6 MicroRNA-targeted therapy via electroporation and 
transfection  
MicroRNA-122 mimics (Ambion, Foster City, CA), heme oxygenase 1 (HO-1)-targeting 
siRNA (Life Technologies, USA) and relevant controls, including siRNA scrambled control 
and miRNA control mimic were introduced to THP1 cells via electroporation using the 
following protocol: 2 × 105 cells were re-suspended in 150 μl complete RPMI media. A 
volume of 150 μl Gene Pulser® electroporation buffer was added and the mixture was kept 
on ice for 5 min. Electroporation was performed immediately after using the previously 
optimized conditions of 300 kV and 1500 μF (Momen-Heravi et al., 2014a). The cells were 
transferred to wet ice for 10 min and then cultured in media for 24 h in 12-well plates 
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(Thermo Fisher). Equimolar amounts of scrambled control oligonucleotide sequences 
(control miRNA mimic; Ambion) were introduced to cells via electroporation using the same 
approach. 
 
MicroRNA mimics and relevant controls were forward transfected into RAW264.7 
macrophages by Lipofectamine RNAiMAX (Life Technologies, USA) based on the 
manufacturer’s protocol for cell transfection. Briefly, cells were transfected at 60 % 
confluency in 6-well plates. Lipofectamine RNAiMAX Reagent (9 µl) was diluted in 150 µl 
Opti-Mem medium (Invitrogen, Waltham, MA). Micro-RNA-122 mimic (3 µl) was added 
to Opti-Mem medium (150 µl). Diluted miRNA-155 mimic was then added to diluted 
Lipofectamine RNAiMAx Reagent (1:1 ratio) and incubated for 5 min. The miRNA-lipid 
complex was added to the cells in a dropwise fashion. The final amounts of miRNA-122 
mimic and Lipofectamine RNAiMAx used per well were 25 pmol miRNA-122 mimic mass 
and 7.5 µl Lipofectamine, respectively. 
 
2.2.7 LPS challenge protocol 
After 48 h the cells were washed and treated with 10 nM LPS (Escherichia coli 0111:B4) 
(Sigma-Aldrich) for 6 h. Relative expression levels of HO-1 were quantified by qPCR and 
tumour necrosis factor alpha (TNFα) protein levels were measured in the supernatants by 
ELISA as described in detail in section 2.2.10. 
 
2.2.8 Kuppfer cell (KC) and liver mononuclear cell (MNC) isolation 
KC were isolated using an established protocol from pair-fed or alcohol-fed animals (n = 8) 
as described previously (Bala et al., 2011). Briefly, the liver was perfused under terminal 
anesthesia with 0.9 % w/v NaCl saline (Sigma-Aldrich) for 10 min, in vivo digestion was 
performed using Liberase enzyme (F. Hoffmann-la Roche, Basel, Switzerland) (40 µg/ml) 
for 5 min at room temperature, followed by an in vitro digestion for 30 min. The non-
hepatocyte fraction of the liver was separated by Percoll density gradient (GE Healthcare, 
Pittsburg, PA) centrifugation. Briefly, the cell pellet was re-suspended in 10 ml of Hanks 
buffer (Thermo Fisher) mixed with 5 ml Percoll and centrifuged at 800 g for 60 min (4 ºC). 
 
The inter-cushion fraction was washed 2 times with DMEM medium (centrifuged at 50 x g 
for 2 min) and adhered to cell culture 150 mm plastic plates (Thermo Fisher) in DMEM 
supplemented with 5% v/v fetal bovine serum. The non-adherent fraction was separated and 
washed, and the adherent KC population was used for downstream analysis or cell culture. 
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Liver mononuclear cells (MNCs) were isolated from another group of mice (n = 8) and 
separated by Percoll gradient using a literature protocol (Hritz et al., 2008). 
 
2.2.9 Pretreatment of THP1 monocytes with miRNA-122 inhibitor 
via exosomes 
The workflow of the series of these experiment included the following: First, exosomes were 
isolated from THP-1 cells and loaded with miRNA-122 inhibitor. miRNA-122 inhibitor 
loaded exosomes were added to the recipient naïve THP1 cells and co-cultured for 12 h with 
exosomes derived from ethanol-treated Huh7.5 cells. Afterwards THP-1 exosomes were 
washed off and ethanol-treated exosomes were added to the recipient THP-1 cells. Briefly, 
exosomes harvested by Exoquick-TC (System Biosciences) as described in section 2.2.4. 
Exosomes were re-suspended to a final concentration of 50 µl/ml in PBS buffer and added 
to Gene Pulser electroporation buffer (Bio-Rad Laboratories) at a 1:1 ratio. Oligonucleotides 
such as microRNA-122 inhibitor (Ambion) or negative control for miRNA inhibitor 
(Ambion) at final amount of 300 pmol were added to the exosome sample containing 1 μg/μl 
exosomal protein. The samples were transferred to a 0.2 ml electroporation cuvettes and 
electroporation was undetaken at 150 kV and 100 μF in a Gene pulser II System (Bio-Rad 
Laboratories). The loaded exosomes were treated with one unit of ribonuclease H (RNase 
H) (1 U/µl) (Thermo Fisher) for 1 h at room temperature to degrade free-floating or surface-
adsorbed oligonucleotides and were re-isolated using ExoQuick-TC™ to a final 
concentration of 50 µg/ml of exosomal protein. Loaded exosomes were quantified by NTA 
and co-cultured with THP1 monocytes at 1 particle per cell ratio. After 12 h of co-culture, 
the exosomes were washed off by centrifugation of cell suspension at 500 x g for 10 min at 
4 ºC. Afterward, the cell pellet was washed for 2 times in 10 ml PBS by centrifugation at 
500 x g for 10 min at 4 °C. After the last wash with PBS, complete 1 ml RPMI media was 
added to the cell pellet and 6 h later exosomes derived from ethanol-treated Huh7.5 cells 
(ethanol exosomes) were added to THP-1 cells in a 1:1 ratio. 
 
2.2.10 Enzyme-linked immunosorbent assay (ELISA) 
Levels of TNFα (BD Biosciences, San Diego, CA), MCP1 (Biolegend, San Diego, CA) and 
Interleukin 1 beta (IL-1β) (R&D Systems, Minneapolis, MN) were measured in cell-free 
supernatants by enzyme-linked immunosorbent assay ELISA based on the manufacturer’s 
recommendations. Briefly, for quantification of human TNFα and monocyte chemoattractant 
protein-1 (MCP1), anti-TNFα (150µl diluted capture antibody) and anti-MCP1 (100µl 
diluted capture antibody) were added to each well of 96-well Nunc-Immuno™ polystyrene 
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Maxisorp ELISA flat bottom plates (Thermo Fisher) and incubated overnight at 4 °C. TNFα 
and MCP1 plates were washed after 16 h 3 times with 300 µl of wash buffer provided by the 
supplier. For IL-1β microplates were coated with 200 µl (5 µg/ml) of a monoclonal antibody 
specific for human IL-1β. 300 µl of samples and standards (with concentration ranging from 
3.9 –2000 pg/ml) were added to the plates and incubated for 2 h at 37 °C. The plates were 
washed 3 times with PBS. IL-1β, TNFα, or MCP-1 conjugate (polyclonal antibody against 
proteins conjugated to horseradish peroxidase) (200 µl) was added and incubated for 1 h at 
room temperature. After 3 more washes, 200 µl of substrate solution (1:1 of hydrogen 
peroxide and tetramethylbenzidine (R&D Systems) was added to the wells and incubated 
for 15 min at room temperature. The reaction was halted by adding 50 µl of stopping reagent. 
Optical densities were measured at 450 nm using a Synergy HTX Multi-Mode Reader 
(Winooski, VT) plate reader and data was processed with Gen5 v. 3.0 Software (Winooski). 
 
2.3 The role of exosomes and miRNA-122 in HCV 
pathogenesis 
2.3.1 Cell lines, primary human hepatocytes (PHH) and HCV 
J6/JFH-1 virus 
Huh7.5 (passage 12), Huh7.0 (passage 11), primary human hepatocytes, and CD81-deficient 
Huh7.25 cells (passage 9) were grown and cultured according to the previously described 
method (Akazawa et al., 2007; Blight et al., 2002). Huh7.5, Huh7.0, and CD81-deficient 
Huh7.25 cells were cultured in T75 flasks in DMEM (Gibco) supplemented with 10 % v/v 
exosome-depleted fetal bovine serum (FBS) (Thermo fisher), and 1 % v/v of 10,000 U/mL 
penicillin/streptomycin (Thermo Fisher). After cells reached 70-80 % confluency, they were 
split 1:2. For splitting, culture medium was removed and cells were washed 3 times with 
5ml PBS. Five ml Trypsin Ethylenediaminetetraacetic acid (EDTA) (Gibco) was added to 
cover the cells at the bottom of the flask. After cell detachment, conditioned media 
containing 10 % v/v FBS was added and cells were seeded at densities of 0.3x106 in 12-well 
plates.  In the exosome experiments, exosome depleted FBS (System Bioscience) was used.  
 
The pFL-J6/JFH1 plasmid which encodes the entire viral genome of a chimeric strain of 
HCV-2a, was obtained from Charles M. Rice laboratory. Xbal (10 U/µL) (Thermo fisher) 
digestion was done to linearize plasmid. The plasmid was transcribed by a T7 RiboMAX 
(Promega, Madison, WI) in order to generate the full length viral genomic RNA. RQ1 
RNase-free DNAse was added in concentration of 1 unit per microgram of template DNA 
and incubated for 15 min at 37 °C. One volume of phenol (pH 4–5):chloroform:isoamyl 
alcohol (125:24:1) (Sigma-Aldrich) was added and vortexed for 1 minute and centrifuged at 
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12000 x g in a microcentrifuge for 2 min. The upper aqueous phase was transferred to a fresh 
tube and 1 volume of chloroform:isoamyl alcohol (24:1) was added and then centrifuged at 
12000 x g for 2 min. The upper aqueous phase was transferred to a fresh tube. A 0.1x volume 
of 3M Sodium Acetate (pH 5.2) and 1 volume of isopropanol or 2.5 volumes of 95 % v/v 
ethanol was added and mixed on ice for 5 min and centrifuged at the top speed in a 
microcentrifuge (~21,000 × g) for 10 min. The supernatant was aspirated and pellet was 
washed with 1 ml of 70 % v/v ethanol. The pellet was dried under vacuum and the RNA 
sample was re suspended in 100 µl nuclease-free water. 
 
The RNA (10 µg) was transfected into Huh7.5 cells by electroporation (280V, 1000µF) 
using a Gene Pulser (Bio-Rad). The Huh 7.5 cells were cultured in complete condition 
medium to produce replication-competent HCV virus (J6/JFH1; genotype 2a) (Lindenbach 
et al., 2005; Mohd-Ismail et al., 2009). 
 
HCV J6/JFH-1 virus and exosome concentrations in culture supernatants were measured 
using a NanoSight LM10 (Malvern). The multiplicity of infection (MOI) of infectious viral 
particles or infectious exosomes was determined by the number of particles and by 
quantitative real-time PCR as described previously (Bukong et al., 2013). 
 
2.3.2 Exosome isolation and purification from patients’ sera and 
cell lines  
Cell culture supernatants (10 ml) or patient sera (500 µl) were collected and centrifuged at 
2500 revolutions per minute (rpm) for 10 min (4 °C) to remove cell debris. The resulting 
supernatants were serially filtered through 0.8 µm, 0.4 µm, and 0.2 µm filters and were 
subsequently loaded into a Amicon Ultra-15 Centrifugal Filter Unit with an Ultracel-100 
membrane (EMD Millipore, Billerica, MA) to be centrifuged using a Beckman GH 3.8 
Swing Bucket Rotor (Beckman Coulter, Brea, CA) for 30 min at 4 °C to concentrate samples 
to 1ml.  These were mixed with the appropriate volume of Exoquick-TC reagent (ratio of 
5:1) (System Bioscience) or Exoquick (System Bioscience) (ratio of 4:1) respectively as 
indicated by the manufacturer for exosome isolation.  
 
HCV infected patients and healthy controls were recruited from the Hepatology clinical unit 
at the University of Massachusetts Medical School (Worcester, MA, USA). This research 
protocol was approved by the institutional review board (#2284). Blood samples were 
collected and serum was analyzed for HCV RNA using RT-PCR. 
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Concentrated culture supernatants (500 µL) or filtered patient sera (150 µL) were mixed 
with 1500 µL of Exoquick-TC reagent (System Biosciences, USA) or 50 µL of Exoquick 
(System Biosciences), respectively. The samples were incubated for 1 h at 4 °C. Exosomes 
were precipitated by centrifugation at 1400 rpm for 10 min at 4 °C and re-suspended in 100 
µl PBS. In the experiments involving the isolation of exosomes from virus suspensions, 
positive selection of exosomes was performed using anti-CD63 immuno-magnetic capturing 
method. Primary anti-CD63 antibody (25 µl) (Abcam, USA) was added to the concentrated 
supernatant (500 µl) and incubated for 4 h at 4 °C. Secondary antibody coupled to magnetic 
beads (50 µl) (Miltenyi Biotec, Auburn, MA) was added to the concentrated supernatant 
(500 µl). LD columns (Miltenyi Biotec) were prewashed with 5 ml of 1x PBS for 3 times 
and columns were attached to the Miltenyi Biotec MidiMACS separator attached to a 
Miltenyi Biotec MultiStand. The column was placed with the column wings to the front into 
the magnetic field of the MidiMACS Separator and exosome suspension was added to the 
column. The column was washed with 5 ml PBS to eliminate other particles not expressing 
CD63. The column was detached and washed with 400 µl of PBS to re-suspend CD63+ 
exosomes. Quantification of the number of virus particles or exosomes was performed using 
a NanoSight LM10 system (NanoSight). HCV RNA copy numbers were quantified by RT-
PCR  previously (Bukong et al., 2013). Briefly, 10 μL of viral RNA was reverse transcribed 
to cDNA (Applied Biosystems, USA). The final reaction volume was 20 μL. Viral cDNA (5 
µl) in addition to pFL-J6/JFH1 plasmid standard (5 µl) were used for qPCR to contain 10, 
100, 1000, 10,000, 100,000, 1000,000, 10,000,000 copies per 5 μL. This standard curve was 
used for quantification of the amount of viruses in exosomes, supernatant, and cells. 
 
2.3.3 Co-immunoprecipitation, RNA Chromatin immuno-
precipitation (ChIP) and analysis of exosomes 
Exosomes purified from cell culture supernatants or patient sera were fixed at room 
temperature with 4 % v/v formaldehyde buffered saline (Sigma-Aldrich). After fixation, 
exosomes were lysed in 100 µl sodium dodecyl sulfate (SDS) ChIP lysis buffer (Millipore), 
supplemented with protease inhibitor (Sigma Aldrich) at a 1:10 ratio and RNase inhibitor 
(Ambion) (1 U/µl) to a final inhibitor concentration of 1 U/µl. Primary anti-Ago2 antibody 
(Anti-Ago2, 10 µg/ml; Abcam, Cambridge, MA) was added to 50 µg of exosomal total 
protein and incubated for 90 min at 4 °C. 20 µg of re- volume of A/G PLUS Agarose beads 
from the stock concentration of 0.5 ml agarose/2.0 ml (Santa Cruz, Dallas, Texas) was added 
to the sample and the tube was incubated on a rocker platform for an additional 60 min at 
4°C.  Immunoprecipitates were collected by centrifugation at 1100 g for 5 min at 4 °C. 
Pellets were washed for three times with SDS ChIP lysis buffer (500 µl) and by repeating 
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1100 g for 5 min at 4 oC centrifugations and pellet re-suspended in 35 µl of 1x electrophoresis 
sample buffer. The immunoprecipitated protein-RNA complexes were used for downstream 
western blot analysis or RNA isolation. 
 
2.3.4 Use of targeted siRNA and miRNA inhibitor therapy and cell 
transfections 
The following siRNA and miRNA inhibitors were used: human heat shock protein 90 
(HSP90) siRNA (Santa Cruz, USA), scrambled control siRNA (Santa Cruz), hsa-miRNA-
122 anti-miRNA miRNA Inhibitor (Ambion, USA) and anti-miRNA Negative Control 
(Ambion, USA). miRNA inhibitors were introduced into Huh 7.5 cells using the liver in vivo 
altogen transfection reagent (Altogen Biosystems, USA).  
 
Evaluation of miRNA inhibitors in Huh7.5 cells was performed using a forward transfection 
protocol at final oligonucleotide concentrations of 30 nM. Briefly, 8x104 cells were plated 
in 12 well plates for 24 h in 1 ml growth media to ensure adherence. Ahead of transfection, 
4 µl of liver in vivo altogen transfection reagent was vortex-mixed with 45 pmol 
oligonucleotide dissolved in RNAse free water (Thermo Fisher) at 100 µl final volume. 
During a 20 min room temperature incubation of the transfection mix, the cells were washed 
3x with 0.5 ml of 1x PBS and fresh media was added (900 µl), supplemented with 100 µl of 
transfection mix at the end of the mix incubation period. Cells and supernatants were 
harvested at the indicated time points.  
 
2.3.5 Use of protease inhibitor and vacuolar-type H+-ATPase 
inhibitor (bafilomycin A1) for the inhibition of HCV infectious 
exosomes and virus 
Using 105 Huh7.5 cells in 12-well plates, Telaprevir (VX-950; Selleckchem, Houston, 
Texas) was added at 10 ng/ml and 20 ng/ml concentrations, 24 h after infection with 1 MOI 
of virus suspension or exosomes derived from HCV-infected hepatocytes. Alternatively, 
Bafilomycin A1 (Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) and 
administered to cells at different concentrations (12.5 nM, 25 nM, 50 nM and 100 nM) with 
the final DMSO concentration of DMSO being 0.01% v/v.  After 1 h, HCV virus suspension 
and exosomes derived from HCV-infected cells were added to the Bafilomycin A1-treated 
Huh7.5 cells at an MOI of 1. After 24 h, the media were removed and cells washed 3 times 
with 1 ml PBS. Viral RNA entry was assessed by performing qRT-PCR (Forward Primer: 5′-
TCTGCGGAACCGGTGAGTAC-3′; HCV Reverse primer: 5′-
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TCAGGCAGTACCACAAGGCC-3’) for detection of positive sense HCV 5′ UTR on 500 
ng RNA extract samples obtained as described in section 2.1.1. 
 
2.4 Salivary miRNA as biomarkers of oral cancer 
2.4.1 Saliva collection and RNA extraction 
This protocol was approved by the Institutional Review Board (Texas A&M 
University/Baylor College of Dentistry; # 0361). The saliva samples were collected from 34 
subjects: 9 oral squamous cell carcinoma (OSCC) patients before surgical resection of 
tumor, 8 patients with oral squamous cell carcinoma in remission (OSCC-R), 8 patients with 
oral lichen planus (OLP), and 9 healthy controls (HCs). Unstimulated saliva was collected 
from the participants between 6 and 11 am, following a previously published protocol 
(Cheng et al., 2011). Briefly, participants were asked to refrain from drinking, eating, or 
applying oral hygiene procedures on the day of saliva collection.  Individuals rinsed their 
mouth with water before saliva collection to minimize contamination of the samples. After 
5 min, the participant sat upright and spat into a 50 mL Falcon tube, which was kept on ice. 
A maximum of 8 mL of saliva was collected from each individual in 30 min. 
 
Saliva samples were centrifuged at 2,600 g for 15 min at 4 °C to remove the cellular debris. 
The RNase inhibitor (SUPERase-In, Ambion, USA) was added to the supernatant (5 µL of 
SUPERase-In per mL of supernatant), as previously described (Hu et al., 2008). RNA 
isolation was done as described in section 2.1.1. 
 
2.4.2 NanoString nCounter miRNA assay for miRNA profiling 
The whole genome multiplexed NanoString nCounter miRNA expression assay (NanoString 
Technologies, Seattle, WA) was used for miRNA profiling according to the manufacturer’s 
protocol. Briefly, 100 ng of total RNA in 3 µl was used as input material. A unique DNA 
tag was ligated onto the 3′ end of each mature miRNA in the samples, providing specific 
identification for each miRNA species present. The tagging was done in a multiplexed 
ligation reaction using reverse complementary bridge oligonucleotides, which disposed the 
ligation of each miRNA to its designated tag. Hybridization reactions were done at 64 °C 
for 18 h with a final concentration of 10 μL Reporter CodeSet, 10 μL hybridization buffer, 
5 μL aliquot from the miRNA sample preparation protocol and 5 μL Capture ProbeSet per 
reaction. Afterwards, excess tags were washed away using a two-step magnetic bead-based 
purification on the nCounter™ Prep Station and the resulting materials were hybridized with 
a panel of fluorescently barcoded reporter probes which were specific to the miRNAs. Levels 
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of miRNAs were quantified with the nCounter Prep Station and Digital Analyzer by 
enumerating individual miRNA- specific fluorescent barcodes. A high-density scan (600 
fields of view) was performed and samples were normalized to the geometric mean of the 
top 100 most highly abundant miRNAs (Leichter et al., 2015). 
 
2.4.3 Real-time quantitative polymerase chain reaction for salivary 
miRNA 
Real-time quantitative polymerase chain reaction (qPCR) was done to validate significant 
candidates obtained by the NanoString nCounter miRNA assay as described in section 2.1.2. 
Significant candidates were determined using Welch’s t-test, which assess the likelihood that 
a set of gene counts is significantly different than the set of background counts. Samples 
were first screened for identifying a stable endogenous normalizer in miRNA profiling data. 
We systematically screened for stability of different miRNAs by testing 10 pooling samples 
and 32 individual saliva samples of different study groups, using the NormFinder algorithm 
version 0.953 (Andersen et al., 2004). NormFinder determines the intragroup and intergroup 
variations using a model-based approach. It combines these two types of variation into a 
stability value, effectively adding the two sources of variation to obtain a practical measure 
of the systematic error of an investigated gene measurement, enabling gene rank ordering 
and grouping. Since miRNA-191 expression levels showed the lowest intragroup and 
intergroup variability, it was used as a reference internal normalizer.  All reactions were run 
in triplicate. The qPCR reactions were carried out in an MJ Research PTC-200 Thermal 
Cycler and miRNA expression was compared using the 2-ΔΔCt method as explained in section 
2.1.3. One-way analysis of variance (ANOVA) was used to assess differential expression 
between groups followed by Tukey's HSD test for pairwise comparison.  
 
2.5 Methods for exosome-based targeted therapy 
2.5.1 Cell culture and exosome isolation 
Murine B cells (M12.4) were used as the source of vehicle exosomes in miRNA inhibitor 
and miRNA mimic studies. M12.4 cells were cultured in an RPMI medium, in addition to 
10 % v/v exosome-depleted FBS (Exo-FBS™, Mountain View, CA, USA), and 1 % w/v 
penicillin / streptomycin (Gibco®). After 12 h, the cells were stimulated by CD40 (5 μg/ml) 
(PeproTech, USA) and Interleukin 4 (IL-4) (50 ng/ml) (PeproTech, USA). Three days later, 
the culture media were collected and exosomes were isolated by Exoquick as described in 
section 2.2.4. RAW 264.7 macrophages were cultured in Dulbecco’s modified medium 
(Invitrogen) plus 10 % v/v FBS at seeding density of 8 x 104 /well/2 ml medium (passage 
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number of 14) in 12-well plates for co-culture experiments. RAW 264.7 macrophages were 
used for exosome production at seeding density of 3 x 106 /12 ml medium in T-75flasks 
(passage number of 14). 
 
2.5.2 Optimizing loading conditions of exosomes with miRNA-155 
mimic 
A PBS suspension of freshly isolated exosomes was diluted in Gene Pulser® (Bio-Rad 
Laboratories, USA) electroporation buffer at a 1:1 ratio. miRNA-155 mimic or negative 
miRNA control 1 (Ambion) at a final mass of 150 pmol was added to 0.25 μg/μl, 0.5 μg/μl, 
1 μg/μl, and 1.5 μg/μl of exosome sample. Cold (4 oC) electroporation cuvettes (gap width: 
0.2 cm) were used and the exosomes were electroporated at various voltages (0.130 kV to 
0.200 kV) at a constant capacitance of 100 μF. After optimization of the voltage, the effect 
of variation in capacitance was assessed. Electroporation was performed using a Gene pulser 
II System (Bio-Rad Laboratories). One unit of RNase H was administered per exosome 
suspension for 1 h to eliminate free floating or surface-adsorbed oligonucleotides. Exosomes 
were next re-isolated using Exoquick-TC™. Synthetic C. elegans (cel)-miRNA-39 (5 µl of 
a 5 fmol/μL stock tube) was spiked during the total RNA isolation process and used to 
normalize the qPCR data as an endogenous control The relative amount of encapsulated 
miRNA-155 was determined using TaqMan® miRNA Assays as described in section 2.1.2. 
 
Next, to determine the most efficient isolation method to re-isolate exosomes after the 
electroporation procedure, we compared the three methods of ultracentrifugation, CD63 
immunomagnetic isolation, and Exoquick-TC™. In the first step, exosomes were isolated 
using CD63 immunomagnetic beads as delineated in section 2.3.2. 150 pmol of miRNA-155 
mimic was electroporated into 50 μg of exosomes. The RNase H was added to the exosome 
suspension for a total duration of 1 h to eliminate free floating, unloaded miRNA-155 mimic. 
Exosomes were re-isolated with different isolation methods including ultracentrifugation, 
immunomagnetic isolation, and Exoquick-TC™. Ultracentrifugation was performed at 
100,000 g for 90 min using fixed angle 75 Ti rotor (Beckman Coulter), at 4°C. Exoquick-
TC™ and immunomagnetic isolation methods were performed as outlined in section 2.2.4. 
Cel-miR-39 (150 pmol) was added to the samples before RNA isolation and RNA isolation 
was done as described in section 2.1.1. The experiments were performed in triplicate and the 
amount of recovered miRNA-155 was quantified by TaqMan® miRNA Assays as described 
in section 2.1.2. The cycle number at which the reaction reached an arbitrarily-placed 
threshold (CT) was determined for each sample and the relative amount of miRNA-155 to 
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cel-miR-39 was described using the equation 2−ΔCT where ΔCt = (CtmiRNA-155 – Ctcel-miR-39) 
(Schmittgen et al., 2008). 
 
In order to quantify the efficacy of loading, B cell derived exosomes were purified and 
loaded with miRNA-155 using the optimal conditions (e.g. voltage and concentrations). 
After loading, exosomes were re-isolated using the Exoquick-TC™ reagent according to the 
manufacturer’s instructions. To remove aggregates of miRNA-155 mimic outside the 
exosomes, the exosome pellet was treated with one unit of RNase H. Exogenous cel-
miRNA-39 was spiked to the samples before RNA isolation and used an exogenous control 
to calculate loading efficiency. Subsequently, the total RNA was extracted. The proportion 
of miRNA-155 mimic that was loaded into the exosomes was calculated using the following 
formula: 
 
𝑓𝑚𝑖𝑅𝑁𝐴−𝐿𝐸 = (
𝑉𝑐𝐶𝑐𝑀𝑊𝑐
𝑉𝑠𝐶𝑠𝑀𝑊𝑠
) (
𝑅𝐸𝑠
𝑅𝐸𝑐
) 
 
Where fmiRNA-LE (miRNA-LE is the miRNA loading efficiency) is the fraction of miRNA 
which was successfully loaded into the exosomes; Vc is the volume of added exogenous 
spiked control; Cc is concentration of exogenous control; MWc is molecular weight of the 
exogenous control; Vs is the volume of electroporated miRNA sample; Cs is the 
concentration of the sample; MWs is the molecular weight of the loaded miRNA-155 mimic; 
REs is the relative expression of miRNA-155 mimic and REc is relative expression of the 
control (spiked cel- miRNA-39). Using this formula, our “optimal” loading protocols led to 
efficient loading of miRNA-155 mimic into the exosomes (55.06%). 
 
2.5.3 Enzyme-linked immunosorbent assay (ELISA)  
TNFα protein levels were measured using a Mouse TNFα ELISA kit (BD Biosciences, USA) 
as described in section 2.2.10. Supernatants (400 µl) were collected from the cells and 
centrifuged at 2000 g for 10 min to remove cellular debris and then frozen at −80 °C until 
use. Protein levels of IL-1β, TNFα, and MCP1 were quantified in the supernatant by ELISA. 
The quantification of TNFα (BioLegends, USA), MCP1 (BioLegend Inc., USA) and IL-1β 
(R&D Systems, USA) were carried out based on the manufacturers’ recommendations using 
a Synergy HTX Multi-Mode ELISA reader. 
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2.5.4 Lactate Dehydrogenase (LDH) cytotoxicity assay 
The lactate dehydrogenase (LDH) level was measured in the supernatant of RAW264.7 
macrophages based on the manufacturer's recommendation (Abcam). Released LDH in 
culture supernatants of RAW macrophages was quantified 36 h after delivery of miRNA-
155 inhibitor via different methods with relevant controls. The percentage of cytotoxicity 
was calculated by subtracting the LDH content in the supernatant of remaining viable cells 
from the total LDH in the supernatant of untreated controls. Staurosporine (20 nM) (Abcam) 
served as a positive control for cell death. The final absorbance was measured at 490 nm 
with a Synergy™ HTX Multi-Mode Microplate Reader. Results were expressed as the mean 
of three independent experiments. 
 
2.6 Biodistribution of miRNA-155 and exosomes 
2.6.1 Animal studies 
Mice deficient in miRNA-155 (miRNA-155 knockouts; KO) and C57/Bl6J wild type (WT) 
(eight- to ten-week old) male or female mice were purchased from Jackson Laboratory 
(Farmington, CT). All experimental protocols were approved by the Institutional Animal 
Use and Care Committee of the University of Massachusetts Medical School (Worcester, 
MA). Female WT mice were injected with saline or 2.5 mg/kg CpG (Sigma-Aldrich) by 
intraperitoneal injection (i.p.) at 24 h intervals for three days to increase miRNA-155 in the 
circulation (Petrasek et al., 2011). On day 4, the mice treated with CpG received 0.5 mg/kg 
LPS (i.p.) 3 h before sacrifice. At the end of treatment, mice were cheek bled and plasma 
was separated from the blood and stored at −80 °C for downstream analysis. The liver and 
other tissues were washed several times with PBS and immediately either snap frozen in 
liquid nitrogen (protein analyses) or diced and placed in RNAlater (Qiagen, USA) for 
downstream experiments. 
 
EDTA-containing microtainer tubes (BD Biosciences) were used for blood collection and 
plasma was isolated by centrifugation at 2000 g for 10 min at room temperature. The 
centrifugation step was performed twice to minimize platelet contamination. The separated 
plasma fraction was aliquoted and stored at −80°C for further analysis. 
 
2.6.2 Tissue collection, perfusion and cell isolation 
At the desired time points of the experiments, various organs were removed, immediately 
washed in PBS, blotted on tissue and stored in RNAlater at −80 °C. Different liver cell 
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populations were isolated after perfusion based on a described protocol (Csak et al., 2011). 
Briefly, mice were anesthetized with ketamine (300 mg/kg, i.p.) and the liver was perfused 
with sterile saline solution for 10 min followed by in vivo digestion with 50 ml of Hanks 
balanced salt solution (HBSS) solution and 0.8 mg/mL of collagenase type 1 (Sigma 
Aldrich) for 5 min. The perfused liver was set on a petri dish containing 15 ml HBSS and 
0.02 % collagenase (Sigma Aldrich) and cells separated. To separate hepatocytes, the cell 
suspension was centrifuged (200 g for 5 min) at room temperature (Csak et al., 2011). The 
pellet containing hepatocytes was washed with 5 ml PBS twice. The cell number was 
quantified with a Beckman Coulter Z1 cell counter (Beckman Coulter, Fullerton, CA) 
according to the manufacturer’s instructions. Hepatocytes were cultured in DMEM Low 
Serum with 1 % w/v Penicillin-Streptomycin (Thermo Fisher) and 10 nM insulin (Thermo 
Fisher). Mononuclear cells and KCs were isolated using an established protocol as described 
in section 2.2.8 and in the literature (Hritz et al., 2008; Bala et al., 2011). 
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Results 
3.1 The role of exosomes in the pathogenesis of 
alcoholic liver disease 
Different liver cells including hepatocytes, KCs, hepatic stellate cells, and sinusoidal 
endothelial cells are affected by the deleterious effects of alcohol and participate in the 
pathogenesis of alcoholic liver disease (Cohen and Nagy, 2011). Immune cells are also 
affected by alcohol and play pivotal roles in the process (Nagy, 2015; Gao and Bataller, 
2011). Thus, alcohol-induced damage has been reported to lead to the release of pro-
inflammatory cytokines, lipid messengers, chemokines, and reactive oxygen species that 
further potentiate cell damage (Brenner et al., 2013). It has been previously shown that 
circulating exosomes in relevant mouse disease models carry miRNA-122 (Bala et al., 
2012), a liver specific miRNA, mainly found in hepatocytes but considerably less so in other 
tissues and other cell types including immune cells: it’s function outside the liver is unknown 
(Lagos-Quintana et al., 2002). Tissue-specific miRNA profiling in different organs has 
previously shown that miRNA-122 represents 70–80 % of the total miRNA in hepatocytes 
(Lagos-Quintana et al., 2002). It has been previously reported that exosomes can be taken 
up by monocytes and modulate their function. For example, exosomes were taken up by 
human monocytic THP-1 cells and transferred their miRNA-223 to those cells. Functional 
activity of miRNA-223 was confirmed by 3′-UTR luciferase reporter vector to which 
miRNA-223 binds (Ismail et al., 2013). We hypothesized that exosomes derived from 
ethanol-exposed hepatocytes can convey messages to monocytes and modulate their immune 
function (Momen-Heravi et al., 2015a; Saha et al., 2015). 
 
3.1.1  Binge alcohol consumption increases the number of 
circulating exosomes in sera of healthy human subjects and mice 
It has been shown that binge alcohol drinking can induce deleterious health effects and rapid 
increase in serum endotoxin and 16S rDNA, a marker of bacterial translocation from the gut, 
as well as increase in circulating inflammatory cytokine profile such as TNF-α, IL-β, and 
MCP-1 (Bala et al., 2014). We thus first evaluated the change in the number of exosomes 
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after binge alcohol drinking. Measurement of exosome numbers in the sera of healthy 
individuals (n = 11) before and after binge alcohol drinking was done at various time points 
(30 min-24 h) by a Nanoparticle Tracking Analysis (NTA) system. These studies revealed 
that the number of exosomes in man increased significantly as early as 30 min after drinking 
and this increase remained statistically significant at other tested time points (1 h, 2 h, 3 h, 
4 h, and 24 h) (Figure 3.1A). Profiling of these exosomes revealed significantly higher levels 
of the liver-specific miRNA-122 specifically, peaking after 4 h of alcohol consumption 
compared to baseline levels. There was no substantial difference in miRNA-122 expression 
level in control subjects at different corresponding time points. Thus, although other 
miRNAs were also elevated in response to binge alcohol consumption, the levels of e.g. 
miRNA-155 peaked at 30 min, suggesting differential exosomal miRNA release kinetics in 
response to alcohol consumption (Figure 3.1B). In stark contrast, control subjects receiving 
the same volume of juice did not exhibit any statistically significant exosome and exosome-
contained miRNA changes across any of the timepoints surveyed.  
 
In mice, binge alcohol consumption induced a significant increase in the total serum number 
of exosomes 6 h and 12 h post ethanol consumption (p < 0.05) (Figure 3.1C). In line with the 
human data, expression levels of exosomal miRNA-122 (12 h) were significantly increased 
compared to saline-fed animals (p < 0.05) (Figure 3.1D). Similarly, in the chronic alcohol 
feeding model, after 5 weeks, the number of circulating exosomes in serum was significantly 
increased compared to the pair-fed control mice (Figure 3.1E), as were the levels of 
exosomal miRNA-122 (Figure 3.1F). 
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Figure 3.1: Effect of alcohol in exosome production in humans and mice. (A) Changes in 
total serum exosome concentration after alcohol binge drinking in healthy human subjects 
relative to pre-drinking levels, as determined by NTA (n=11). Units are given in RU 
(Relative Units) (B) Serum exosomal miRNA-155 and miRNA-122 levels in humans during 
a 24 h binge drinking alcoholic challenge study. (C) Exosome levels in mouse sera 6 h and 
12 h after binge alcohol drinking as determined by NTA. (D) Exosomal miRNA levels in 
mouse sera after a binge-ethanol feeding challenge. (E) Effect of chronic alcohol feeding 
(n=6) for 5 weeks on serum exosomes as quantified by NTA. (F) miRNA-122 levels in 
mouse serum exosomes after a 5 week alcohol diet. The results were averaged from three 
independent experiments. (*indicates p < 0.05 versus control conditions)This figure is 
adapted from Momen-Heravi et al., 2015, Scientific reports 
 
3.1.2 The number of exosomes correlates with ALT levels  
Serum exosome concentration (particles/ml) showed a strong and statistically significant 
correlation with ALT levels (IU/L) (Spearman’s Rho, r = 0.8; p < 0.05; Figure 3.2A). A 
significant fraction of total serum RNA was associated with the serum-exosomes compared 
to the exosome-depleted serum (Figure 3.2B). 
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Figure 3.2: Correlation between the number of exosomes and ALT level and relative RNA 
yield of exosomes. (A) Correlation between serum ALT level and exosome number in the 
sera of chronically alcohol-fed mice. (B) Fraction of total RNA associated with exosomes in 
pair-fed and control mice, expressed relative to the geometric mean of total RNA yield from 
exosome depleted serum. Relative amount of total RNA associated with exosome fraction 
was calculated with regards to that geometric mean.  
This figure is adapted from  Momen-Heravi et al., 2015, Journal of Translational Medicine 
 
3.1.3 Alcohol increases the exosome production in hepatocytes 
Treatment of Huh 7.5 cells with various concentrations of ethanol as a model of human 
alcohol consumption (25 mM:  moderate consumption; 50 mM:  heavy consumption; 
100 mM binge/chronic consumption) showed a significant increase in the number of 
exosomes at different time points post ethanol exposure (24 h, 48 h, and 72 h; p < 0.05; 
Figure 3.3 A, B, C) in both a dose- and time-dependent manner. Accordingly, the mRNA 
expression level of Rab 27b, the protein that plays a role in late endosomal formation 
(Ostrowski et al., 2010), was significantly increased after ethanol exposure (p < 0.05), 
suggesting activation of exosome biogenesis pathways by alcohol treatment (Figure 3.3D). 
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Figure 3.3: The effect of ethanol on the production of exosomes by Huh7.5 cells. Cells were 
exposed to increasing concentrations of ethanol ahead of collection and analysis of exosomes 
by NTA at 24 (A), 48 (B) and 72 hrs (C). (D) The level of Rab27b was quantified by qRT-
PCR in Huh7.5 cells 48 h after 100 mM ethanol treatment. (E) TEM of exosomes isolated 
from Huh7.5 cells isolated after 48 h of 100 mM ethanol treatment (scale bar: 50 nm). The 
arrow indicates a single exosome. (F), (G) Exosome size distribution identified with NTA. 
(H),(I),(J) SEM of exosomes produced by Huh 7.5 cells treated with 100 mM ethanol for 48 
h. SEM Scale bars: 30 µm (H,I), 5 µm (J). Statistically significant changes in exosome 
release or gene expression are indicated by ‘*’ (p < 0.05 compared to the control conditions). 
This figure is adapted from Momen-Heravi et al., 2015, Scientific reports. 
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3.1.4 Characterization of exosomes derived from cultured and 
primary hepatocytes  
Given dose and time dependent exosome release effects were most prominent under the 
binge/chronic consumption model conditions, further analysis was focused to this aspect of 
the disease.  Exosomes derived from Huh7.5 cells had diameters in the range of 50–150 nm 
and showed the previously described liposome-like morphology on TEM (Momen-Heravi 
et al., 2012a) (Figure 3.3E). The mean vesicle size was 90 nm and they expressed the 
exosomal marker CD63 (Figure 3.3 F&G). Scanning electron microscopy (SEM) showed an 
increased number of exosomes after ethanol treatment in accordance with NTA 
measurements. (Figure 3.3H). 
 
RNA size profiling showed an increase in exosomal small RNA cargo after ethanol treatment 
(100 mM) which was also observed with small RNAs (Figure 3.4 A-C). Given miRNA-122 
is the principally expressed miRNA in Huh7.5 cells, we investigated miRNA-122 expression 
in this system. Thus, treatment of Huh 7.5 cells with ethanol resulted in a slight increase in 
cellular miRNA-122 levels, however, exosomes derived from ethanol-exposed Huh7.5 cells 
demonstrated significantly elevated levels of miRNA-122 (p < 0.05; Figure 3.4C and D). In 
contrast, the level of miRNA-29b was significantly decreased in the exosome fraction after 
ethanol exposure (p < 0.05; Figure 3.4E). MicroRNA 29b has been reported to play roles in 
the pathogenesis of liver diseases such as biliary atresia, liver fibrosis and cirrhosis (Szabo 
and Bala, 2013). This data indicated that miRNA sorting into the exosomes is a regulated 
and specific process. 
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Figure 3.4: Characterization of exosomal small RNA and miRNA cargo in Huh 7.5 cells 
and primary human hepatocytes. (A-F) The graphs represent results obtained from an 
Agilent bioanalyzer small RNA kit, characterizing the distribution of the RNA cargo of 
exosomes. (A-C) Represents the small RNA profile in the control exosomes derived from 
Huh7.5 cells in three different specimens. (D-F) Represents the small RNA profile in the 
exosomes derived from ethanol-exposed Huh7.5 cells in three different samples. The 
difference in distribution of non-coding RNAs in exosomes derived from ethanol-exposed 
cells compared to exosomes derived from control cells is annotated by gray boxes in the 
graphs. (G) Levels of miRNA-122 were quantified in the Huh 7.5 cells treated with ethanol 
(100 mM) and control cells using a TaqMan® miRNA assay. (H) Levels of miRNA-122 
were quantified in the exosomes derived from ethanol-treated (100 mM) Huh7.5 cells and 
control exosomes using a TaqMan® miRNA assay. (I) The levels of miRNA-29b were 
quantified in the exosomes derived from ethanol-exposed (100 mM) Huh7.5 cells and 
control exosomes by a TaqMan® miRNA assay. (J) The total number of released exosomes 
was quantified in primary human hepatocytes treated with different dosages of ethanol 
(25 mM, 50 mM, and 100 mM) for 48 h by an NTA system. The total number was shown as 
particles/ml. (K) The levels of miRNA-122 was quantified in the exosomes derived from 
primary human hepatocytes after administration of ethanol (50 mM for 48 h) by a TaqMan® 
miRNA assay. (L) The levels of miRNA-29b in the exosomes derived from primary human 
hepatocytes were quantified after administration of ethanol (50 mM for 48 h) by a TaqMan® 
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miRNA assay. The results are obtained from three independent experiments. (*indicates 
p < 0.05 compared to the control conditions) 
This figure is adapted from Momen-Heravi et al., 2015, Scientific reports 
 
To validate the cell culture findings, we next evaluated exosome production in primary 
human hepatocytes after ethanol exposure. Thus, repetition of the studies ranging 25-100 
nM [EtOH] recapitulated both the increased exosome production and altered miRNA-122 
and miRNA-29b gene expression changes (p < 0.05) (Figure 3.3 J-L).  
 
3.1.5 Exosomes derived from ethanol-treated hepatocytes 
horizontally transfer mature miRNA-122 to monocytes 
To investigate the function of these ethanol-induced, hepatocyte-derived exosomes with 
respect to the immune system, exosomes derived from ethanol-exposed Huh7.5 were co-
cultured with a monocytic cell line. Thus, co-culture of PKH2 (green fluorescent cell linker) 
labeled hepatocyte-derived exosomes resulted in uptake of exosomes by THP-1 monocytes 
after 6 h, as shown by confocal microscopy (Figure 3.5). 
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Figure 3.5: Confocal microscopy, fluorescent labeled exosomes were taken up by THP1 
monocytes. Exosomes were fluorescently labeled with PKH67 (A, green) and co-cultured 
with THP1 monocytes for 6 h. DAPI was used for the staining of nuclei (B). Nomarski 
Interference Contrast (NIC) was used for visualizing the cytoplasm (C). THP1 monocytes 
had taken up exosomes, which was indicated by the presence of green fluorescently labeled 
exosomes in the cytoplasm of the THP1 cells after merging the images (D). 
(Magnification:40k) 
This figure is adapted from Momen-Heravi et al., 2015, Scientific reports 
 
Furthermore, the observed exosome uptake resulted in a 5–8 fold increase in the expression 
level of the mature form of miRNA-122 in THP1 monocytes, in an alcohol and TLR4 
signaling-independent fashion as indicated through relevant controls (Figure 3.6A). To 
preclude the possibility this was on account of miRNA-122 transcription induction in the 
exosome-receiving THP1 cells we measured the expression levels of pri-miRNA-122. Thus, 
whilst Pri-miRNA-122 was exclusively detected in hepatocytes, transcript levels were below 
the assay detection limit in the THP-1 cells irrespective of stimulus used (Figure 3.6B). In 
line with these in vitro findings, KCs and liver mononuclear cells (MNCs) isolated from 
chronic alcohol-fed mice revealed increased levels of miRNA-122 compared to the control 
pair-fed mice (Figure 3.6C&D). 
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Figure 3.6: Horizontal transfer of mature form of miRNA-122 to the THP1 cells by ethanol-
treated Huh7.5 cells. (A) Exosomes were added to the THP1 cells for 8 h and after that 
exosomes were washed off and the culture media was replaced. Levels of miRNA-122 were 
quantified in THP1 monocytes by a TaqMan® miRNA assay. RNU-48 was used as internal 
control to normalize the Ct values between the samples. (B) pri-miRNA-122 in THP1 
monocytes was quantified by a TaqMan® Pri-miRNA Assay. The positive control was RNA 
extracted from Huh7.5 cells. GAPDH was used as an internal control normalizer for real-
time qPCR. (C) Liver mononuclear cells (MNCs) were isolated and miRNA-122 levels were 
compared between ethanol-fed (5 weeks) mice and pair-fed (control) mice (n = 8). 
snoRNA202 was used as a normalizer of Ct values between the samples. (D) Levels of 
miRNA-122 were compared between ethanol-fed (5 weeks) mice and pair-fed (control) mice 
in isolated Kupffer cells (n = 8). Ct values between the samples were normalized based on 
snoRNA202. (E) Expression levels of Heme oxygenase 1 (HO-1) mRNA, reciprocal target 
of miRNA-122, were quantified in different experimental groups using qPCR. 18S was used 
as an internal normalizer. The results were obtained from three independent experiments. 
(*indicates p < 0.05 compared to control conditions) 
This figure is adapted from Momen-Heravi et al., 2015, Scientific reports 
 
3.1.6 Exosome-mediated transfer of miRNA-122 can modulate 
monocyte function 
Although these results confirmed uptake of exosomal miRNA-122 by monocytes after 
hepatocyte injury with alcohol, the functional relevance of this phenomenon remained 
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unresolved. HO-1 has been previously described to be a target of miRNA-122 as evidenced 
through reciprocal expression of these two molecules (Shan et al., 2007; Yachie et al., 2003; 
Drechsler et al., 2006). Mechanistically, transfection of hepatocytes with antagomir of 
miRNA-122, 2’-O-methyl-antagomir miRNA-122, into Huh-7 cells, resulted in increased 
HO-1 levels in hepatocytes. Interestingly, inhibition of miRNA-122 also decreased 
Bach1which is a repressor of HO-1. HO-1 has been shown to have inhibitory effects on 
reactive oxygen species- and cytokine-mediated cell damage (Yachie et al., 2003; Li et al., 
2012b). Accordingly, miRNA-122-containing, ethanol-induced hepatocyte exosomes 
resulted in the significant decrease of HO-1 levels in exosome-receiving THP-1 cells (Figure 
3.6 E). To examine the relationship of hepatocyte alcohol injury with the inflammatory 
functions of monocytes, the impact of alcohol-induced exosomes was assessed in the 
cytokine response of THP-1 cells stimulated with LPS. Significantly, these studies revealed 
an amplification effect on both the mRNA and protein production of TNFα and IL-1β by 
THP-1 cells (p < 0.05). Crucially, these effects were dependent on alcohol stimulation of the 
exosome producing hepatocytes, as normal exosomes failed to amplify the LPS-induced 
THP-1 pro-inflammatory response (Figure 3.7 A, B, C, D). 
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Figure 3.7: Immunomodulation effects of ethanol-treated hepatocytes on human THP1 
monocytes. 100 mM ethanol was added to the Huh7.5 cells for 48 h. Exosomes were isolated 
by a combination of filtration and ExoQuick-TC™ as described in Chapter 2. Exosomes 
derived from ethanol treated cells and non-ethanol treated cells (normal exosomes) were 
administered to the THP1 human monocytes for 8 h. After 8 h, exosomes were washed out 
and the culture media was replaced. RNA and cell supernatant were harvested after 16 h and 
analyzed for downstream measurements. LPS (10 nM) was added to the THP1 monocytes 
6 h before harvesting. (A) Levels of TNFα mRNA were quantified using a quantitative real-
time PCR (qPCR). 18S was used as internal normalizer to normalize the Ct values between 
the samples. (B) TNFα protein levels in the supernatant were quantified by ELISA. (C) The 
levels of IL-1β mRNA expression in THP1 monocytes were quantified by a qPCR. 18S was 
used to normalize the Ct values between the samples. (D) The levels of IL-1β protein level 
in the supernatant were quantified by ELISA. (E) The levels of MCP1 protein in the 
supernatant were quantified by ELISA. (F) The expression level of NADPH oxidase 2 
(Nox2) mRNA in the THP1 monocytes was quantified with a qPCR. The Ct values were 
normalized based on 18s. (G) HO-1 siRNA and scrambled siRNA control were introduced 
to the THP-1 cells by electroporation. Cells (2 × 105) were re-suspended in 150 μl complete 
RPMI media in addition to 150 μl Gene Pulser® Electroporation buffer. The mixture was 
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kept on ice for 5 min before electroporation. Electroporation was done at the optimal setting 
(300 kV and 1500 μF). After electroporation, cells were kept on ice for 10 min and were then 
seeded in the plate for 48 h. 10 nM LPS was administered to the THP1 cells 6 h before 
harvesting in the pertinent groups. Ethanol exosome was added 24 h before harvesting. After 
48 h, levels of IL-1β protein were quantified by an ELISA. (H) After knockdown of HO-1 
by introducing siRNA to the THP1 monocytes as delineated in the previous section, total 
RNA was extracted and levels of Nox2 mRNA expression were quantified using a qPCR. 
18S was used to normalize the Ct values between the samples. The results were obtained 
from three independent experiments. (*indicates p < 0.05 compared to control 
condition)This figure is adapted from Momen-Heravi et al., 2015, Scientific reports 
 
These findings suggested that exosomes derived from ethanol-exposed hepatocytes may 
increase sensitivity of THP1 monocytes toward an LPS challenge. Unlike TNF-α and IL-1β, 
MCP1 protein induction was directly induced by exposure of THP-1 cells to ethanol-induced 
hepatocyte exosomes, with no amplification of the LPS-induced MCP1 production effect; 
again, this response was dependent on ethanol stimulation of the exosome producing 
hepatocytes and not on account of direct ethanol exposure (Figure 3.7 E).  
 
NADPH oxidase (Nox2) is a superoxide generating enzyme which is involved in the 
production of cellular machinery producing reactive oxygen species and plays an important 
role in the host defense (Bae et al., 2011). Nox2 is predominantly expressed in immune cells 
and its expression is controlled by HO-1, and induction of HO-1 suppresses activation of 
Nox2 (Datla et al., 2007; Soucy-Faulkner et al., 2010). HO-1 deficient mice showed 
increased expression of Nox2 and oxidative stress (Wenzel et al., 2015). In line with the 
observation of a sensitizing effect of exosomes derived from ethanol-exposed Huh7.5 cells, 
ethanol exosomes induced a statistically significant increase in the Nox2 levels in THP1 
monocytes compared to the control groups, in the presence of LPS stimulation (Figure 3.7F). 
Collectively, these data indicated a chain of molecular events beginning with the uptake of 
bioactive miRNA-122 by THP-1 cells exposed to the ethanol-induced hepatocyte exosomes, 
which suppressed HO-1 expression, which in turn allowed overexpression of NOX2 (Figure 
3.8). 
 
To test this hypothesis, the effect of si-RNA mediated HO-1 suppression was examined on 
the LPS-driven THP-1 immune response. Accordingly, an increase in IL-1β protein levels 
in the presence of LPS was further enhanced through ethanol exosomes (Figure 3.7G). 
Effective knockdown of HO-1 resulted in a significant increase in Nox2 levels in the 
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presence of LPS and LPS + ethanol exosomes (Figure 3.7H). These data highlights 
suppressive role of HO-1 as regulator of inflammatory and ROS responses. Overall, these 
observations suggest the successful horizontal transfer of liver specific miRNA-122 from 
hepatocytes after ethanol treatment via exosomes. This miRNA-122 is functional and is able 
to modify THP1 responses to LPS through modulating the HO-1 pathway (Figure 3.8). 
 
Figure 3.8: A schematic representation of the improved understanding of the functional role 
of exosomal miRNA-122 in the regulation of monocyte proinflammatory responses to 
alcoholic hepatocyte injury. 
 This figure is adapted from Momen-Heravi et al., 2015, Scientific reports. 
 
To additionally confirm that the introduction of miRNA-122 to THP1 monocytes can 
modulate HO-1 and sensitize monocytes to LPS, a “simulation experiment” was designed. 
miRNA-122 was introduced to THP1 human monocytes and RAW264.7 macrophages by 
electroporation and transfection reagents, respectively (Figure 3.9A). Delivery of miRNA-
122 mimic into the monocytes, resulted in significantly higher protein levels of pro-
inflammatory cytokines TNFα and IL-1β in the presence of LPS stimulation in THP1 cells 
(p < 0.05) (Figure 3.9B&C). This imitated the sensitizing impact that we found in the 
presence of exosomes derived from ethanol-exposed hepatocytes, which are highly enriched 
in the mature form of miRNA-122. 
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Figure 3.9: Simulation experiments to substantiate the induction of pro-inflammatory 
phenotype due to the miRNA-122 transfer and preventing pro-inflammatory effects of 
exosomes derived from ethanol exposed hepatocytes using exosome-mediated RNAi 
delivery. (A) A “simulation experiment” was designed to confirm that pro-inflammatory 
phenotype is due to the horizontal transfer of miRNA-122. miRNA-122 mimic was 
introduced to RAW264.7 macrophages and THP1 monocytes by transfection reagents and 
electroporation, respectively. (B) Electroporation (300 kV and 1500 μF) was used to 
introduce miRNA-122 mimic and control mimic to the THP1 cells. After 18 h, 10 nM LPS 
was added for 6 h and IL-1β ELISA analysis was performed on the supernatants. The results 
were obtained from three independent experiments and expressed as mean±SD of relative 
IL-1β protein levels. (C) Electroporation (300 kV and 1500 μF) was used to introduce 
miRNA-122 mimic and control mimic to the THP1 monocytes. After 18 h, LPS (10 nM) was 
added for 6 h and after that supernatants were collected for TNFα ELISA analysis. The 
results were obtained from three independent experiments and are expressed as TNFα 
protein level fold change. (D&E) miRNA-122 mimic and negative control mimic were 
introduced to the RAW264.7 murine macrophages with Lipofectamine® RNAiMAX 
transfection reagent. LPS (10 nM) was added 6 h before readings. After 48 h, mRNA 
expression levels of HO-1 were quantified by a quantitative real-time PCR. TNFα protein 
levels were measured by quantitative real-time PCR. Ct values between the samples were 
normalized based on 18S. (F) miRNA-122 inhibitor was electroporated into THP1-derived 
exosomes under optimal conditions, as described in Chapter 2. Loaded exosomes were added 
to the naïve THP1 cells for 12 h. After 12 h, exosomes were washed off and the media was 
replaced. Exosomes derived from ethanol-exposed Huh7.5 cells were added for 8 h. TNFα 
protein level was quantified in supernatants after 24 h. 6 h before readout 10 nM LPS was 
added. Positive control was directly electroporated miRNA-122 mimic into the THP1 
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monocytes. The results were obtained from three independent experiments. p<0.05 was 
considered statistically significant and is denoted in the figures. 
This figure is adapted from Momen-Heravi et al., 2015, Scientific reports. 
 
Transfection of RAW264.7 macrophages with a miRNA-122 mimic by Lipofectamine lead 
to a significantly decreased expression level of HO-1 mRNA (p < 0.05) and increased TNFα 
protein levels (p < 0.05), compared to the control group transfected with negative control 
miRNA (Figure 3.9D and E). These results mechanistically confirm the observations 
regarding horizontal transfer of miRNA-122 by exosomes derived from ethanol-treated 
hepatocytes to immune cells and observed pro-inflammatory cytokine production through 
modulation of the HO-1 pathway. In conclusion, given the fact that miRNA-122 exert 
function in monocytes by reducing HO-1 level, these data suggest that exosomal miRNA-
122 derived from ethanol exposed hepatocytes is biologically active in monocytes, 
mediating an amplification of both the proinflammatory and ROS responses. 
 
Based on our results, we hypothesized that the exosomal miRNA-122 function in THP-1 
cells could be blocked by pretreatment of the THP-1 cells with antimiRNA-122. I previously 
developed a successful delivery of an exosome-mediated RNA targeted therapy, both in vivo 
and in vitro, which will be discussed in section 3.4 in detail. Using previously optimized 
methodology (Momen-Heravi et al., 2014a), THP1 derived exosomes were exploited as 
vehicles for the delivery of a miRNA-122 antisense inhibitor. Thus, the effect of anti-
miRNA-122-loaded, THP-1-derived exosomes were assessed in this cell culture model of 
monocyte pro-inflammatory response to hepatocyte exosomes. In line with our hypothesis, 
use of these anti-miRNA-122-loaded exosomes significantly diminished the effects of 
ethanol-induced hepatocyte exosomes in terms of TNFα protein production (p < 0.05) 
(Figure 3.9 F).  
 
3.2 The role of exosomes in HCV transmission 
HCV infection is one of the most burdensome diseases in the world (Lavanchy, 2011). 
Hepatitis C virus infection can induce severe complications, such as liver cirrhosis and 
hepatocellular carcinoma (de Oliveria Andrade et al., 2009). It is estimated that 2–3 % of the 
world's population (nearly 170 million people) is infected with HCV, and more than 350,000 
deaths occur annually due to HCV-related conditions, including hepatocellular carcinoma 
and liver cirrhosis (Averhoff et al., 2012; Lavanchy, 2011). Although HCV infection 
prevalence is reported to be <2% in United states and western Europe, HCV infection rates 
are higher (≥3%) in many countries in Latin America, eastern Europe and certain countries 
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in Africa. Egypt is reported to have the highest rate of hepatitis C in the world (estimated at 
>10%) (Averhoff et al., 2012). Although liver transplantation was introduced as a successful 
treatment, HCV re-infection of the newly transplanted liver is a common phenomenon 
(Vinaixa et al., 2013). Recent therapies with anti-HCV E1-E2, anti-CD81 and other 
neutralizing antibodies were not completely effective and suggested alternative means by 
which the virus could escape the immune system in the circulation and mediate infection 
(Timpe et al., 2008; Morin et al., 2012). Based on our observations and observations made 
by others of controlled RNA shuttling between cells via exosomal communication pathways 
(Momen-Heravi et al., 2015a) and role of exosomes in transmission of  HIV (human 
immunodeficiency virus) (Wiley and Gummuluru, 2006), we postulated that exosomes 
derived from HCV-infected hepatocytes or infected patient sera might carry viral RNA and 
have the ability to mediate HCV transmission (Bukong et al., 2014). 
 
3.2.1 Separation of HCV infected exosomes from free HCV viruses 
and exosome characterization 
HCV is an enveloped, positive-strand RNA virus which is member of the genus Hepacivirus 
within the family of Flaviviridae. Electron microscopy (EM) studies have indicated that 
HCV virions are 40–80 nm in diameter (Lindenbach and Rice, 2013). One of the challenges 
in this study was the limitations in methodology regarding the isolation of pure exosomes vs 
viral particles. Importantly, HCV virions and exosomes have very similar densities and 
diameters (Bartenschlager et al., 2011; Catanese et al., 2013). Thus, the traditional 
ultracentrifugation and sucrose gradient isolation methodology was inadequate for 
segregating the two vesicle sub-populations. To address this, I developed a new method 
based on the combination and optimization of the precipitation method with the CD63 
immuno-magnetic isolation to purify exosomes devoid of free virus from both cell culture 
supernatants (HCV J6/JFH-1 infected Huh7.5 cells) and HCV infected patient sera. Briefly, 
serial filtration (0.8 µm, 0.44 µm and 0.22 µm) was followed by exosome pelleting using 
the Exoquick-TC method (section 2.2.4) followed by immuno-magnetic selection for CD63+ 
to exclude virus carry-over. Isolated exosomes were analyzed by transmission electron 
microscopy, and NTA, demonstrating a vesicular shape and size range between 50 and 100 
nm, in line with the previously described morphology of exosomes (Figure 3.10). 
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Figure 3.10: Characterization of exosomes derived from Huh7.5 cells. TEM(A) and NTA 
analysis(B) of exosomes derived from Huh7.5 cells confirm the morphology and size range 
of 50-100 nm; TEM scale bar:100 nm 
Apolipoprotein E (APOE) is required for HCV virion infectivity and production. It has been 
reported that HCV virions are assembled as APOE-enriched lipoprotein particles (Chang et 
al., 2007). Apolipoprotein B is considered an exosome surface marker (Carayon et al., 2011). 
Consistently, HCV exosomes were enriched in Apolipoprotein B (APOB) which was absent 
from cell-free HCV virus preparations (Figure 3.11A). In contrast, Apolipoprotein E 
(APOE) was strongly associated with the HCV virus fraction and was significantly lower in 
the exosome fraction (Figure 3.11B). These observations suggested adequate separation of 
viral particles from the exosome fraction. 
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Figure 3.11: Comparative analysis of exosome and virus for APOE and APOB proteins. 
Exosomes and cell free virus were purified as described in Chapter 2. Equal numbers of 
exosomes and cell free virus were lysed in RIPA buffer and proteins were extracted. (A&B) 
ELISA for APOE and APOB was done according to the manufacturer’s protocol. APOB 
was detectable in exosomes. There was not a significant difference in APOB contact between 
HCV exosomes versus control exosomes. HCV viral particles showed significantly higher 
levels of APOE compared to exosomes derived from HCV infected cells and control 
exosomes. Results are presented as mean ± SD and are the result of 3 independent 
experiments. (ND: Not detectable; NS: Not significant; p<0.05 was considered statistically 
significant)This figure is adapted from Bukong and Momen-Heravi et al., 2015, PLoS 
Pathog. 
 
3.2.2 Exosomes containing HCV are enriched in Ago2 and miRNA-
122 and can induce active infection 
In line with recent studies reporting that Ago2, HSP90, and miRNA-122 contribute to the 
HCV life cycle (Wilson et al., 2011; Henke et al., 2008; Jopling et al., 2005), exosomes 
derived from HCV-infected Huh 7.5 cells contained higher levels of miRNA-122 (Figure 
3.12A) and Ago2 protein (Figure 3.12B) compared to exosomes from non-infected cells. 
HSP90 levels were also elevated compared to the control exosome population, albeit at 
overall lower levels compared to Ago2 (Figure 3.12B). Similarly, serum exosomes purified 
from HCV infected, treatment-naïve and treatment non-responder subjects were rich in Ago2 
and HSP90 in comparison with control healthy subjects (Figure 3.12C). In contrast, this was 
not observed in HCV treatment responders. Follow on CHIP analysis showed HSP90 and 
Ago2 formed complexes within HCV-containing exosomes, in line with the reports these 
proteins might stabilize the HCV genome replication complex (Figure 3.13). 
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Figure 3.12: Exosomes isolated from HCV infected Huh7.5 cells and sera of HCV infected 
patients harbor HCV RNA, miRNA-122, HSP90 and Ago2. (A) miRNA-122 was 
significantly higher in exosomes derived from HCV J6/JFH1 infected Huh 7.5 cells 
compared to the exosomes derived from control Huh7.5 cells (B) Exosomes derived from 
HCV infected cells showed higher level of Ago2 compared to exosomes from non-infected 
cells. HSP90 levels were also elevated compared to the control exosome population, albeit 
at overall lower levels compared to Ago2 (C) Similarly, serum exosomes purified from HCV 
infected, treatment-naïve (Tx naïve) and treatment non-responder (Tx non-responders) 
subjects were rich in Ago2 and HSP90 in comparison with control healthy subjects. Patients 
were either treatment naïve (Tx naïves), responding (Tx responders), or non-responding (Tx 
non-responders). (p<0.05 was considered statistically significant). The data was obtained 
from three independent experiments. 
This figure is adapted from Bukong and Momen-Heravi et al., 2015, PLoS Pathog. 
 
To determine whether HCV RNA was indeed shuttled to exosomes from infected 
hepatocytes, we next attempted to detect this by qRT-PCR in both cell culture derived and 
patient exosomes. Although qRT-PCR detection of HCV RNA implies transfer of the HCV 
genome to exosomes, this does not confirm whether the genome is physically intact and/or 
capable of replication and virion production. We thus resorted to testing the ability of these 
exosomes to mediate active HCV infection to uninfected Huh 7.5 cells and primary human 
hepatocytes. At first instance we established HCV exosome infectivity in cultured cells by 
serially passaging HCV exosome fractions across 2 uninfected Huh 7.5 cultures. Thus, 
exosomes from HCV-infected Huh7.5 cells were co-cultured with naïve Huh 7.5 cells for 12 
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h, and after another 24 h exosomes produced from the receiving cells were harvested and 
sub-cultured into a new, naïve Huh 7.5 culture (Figure 3.14A). Up to 107 genome equivalents 
of HCV were detected in the final recipient Huh 7.5 cells. In stark contrast, no HCV genome 
was detected in cells receiving exosomes from naïve cells. Similarly, comparable levels of 
infectivity were observed when HCV exosomes were tested against HCV virions at 
comparable mass ratios (Figure 3.14B). Significantly, replication was inhibited by a known 
HCV protease inhibitor, indicating either HCV protease protein inclusion, or translation-
compatible HCV RNA inclusion in the exosomal fraction.  
 
 
Figure 3.13: Exosomes from HCV infected Huh7.5 cells and sera of HCV infected patients 
contain replication competent HCV RNA, miRNA-122 and RISC complexes that enhance 
HCV infection. RNA ChIP analyses of Ago2 in exosomes isolated either from culture 
supernatants of HCV J6/JFH-1 infected Huh7.5 cells or from patient sera were subjected to 
Ago2 pull down followed by total RNA isolation which was analyzed for (A) miRNA-122 
expression (B) Co-Immunoprecipitation of Ago2 and HSP90 complexes from exosomal 
protein lysate isolated from patient sera or culture supernatants of HCV J6/JFH-1 infected 
Huh7.5 cells. Rabbit IgG non-specific antibody served as IP control antibody. Experiments 
are representative of 3 independent experiments for cell culture supernatants and patient 
samples. 
This figure is adapted from Bukong and Momen-Heravi et al., 2015, PLoS Pathog. 
 
Next, we validated these findings in a similar study with primary hepatocytes by harvesting 
serum exosomes from HCV patients (+/- treatment and response) and evaluating their 
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infectivity in naïve primary human hepatocytes. Thus, 48 h post patient serum exosome 
exposure, substantial and comparable quantities of viral RNA were detected in cells treated 
with treatment-naïve and treatment non-responder patient serum exosomes (Figure 3.14C). 
Similarly, HCV RNA copy number at, or above the sample size limit of detection for patient 
serum exosomes resulted in log-scale increases in recipient primary hepatocyte HCV RNA 
levels (Figure 3.14D). Furthermore, the patient sera equivalent experiment comparing the 
infectious potential of HCV exosomes versus HCV virus in the presence or absence of HCV 
protease inhibitor (Figure 3.14E) resulted in comparable data to that obtained with culture-
derived HCV and Huh 7.5 cells (Figure 3.14B). 
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Figure 3.14: Exosomes derived from HCV J6/JFH-1 infected Huh7.5 cells transmit HCV 
infection to the human hepatoma cell line (Huh7.5 cells) and exosomes from sera of HCV 
infected patients transmit HCV infection to primary human hepatocytes. (A) Exosomes 
derived from HCV J6/JFH-1 infected Huh7.5 cells were added to Huh7.5 cells for 12 h, as 
well as different controls. After 12 h, exosomes were washed off and the culture media was 
replaced and cells were cultured for another 24 h. Afterwards, culture supernatants from 
these exosome-infected Huh7.5 cells were transferred to Huh7.5 cells and cultured for 24 h. 
Huh7.5 Cells were harvested and total RNA was extracted and HCV RNA was just 
detectable in exosomes derived from infected cells, determined by a qPCR. (B) The same 
starting amount of HCV virus or HCV exosomes was added to Huh 7.5 cells for 6 h. The 
media were replaced after 6 h and cells were cultured for the indicated time, with or without 
treatment with Telaprevir (VX-950) at the indicated concentration. The cells were lysed. 
Total RNA was extracted and analyzed by qPCR for HCV RNA. Viral replication was 
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inhibited by a known HCV protease inhibitor.  (C) Exosomes were isolated from sera of 
three different patient groups (treatment non-responders, treatment naive, and treatment 
responders) and co-cultured with primary human hepatocytes (PHH). After 8 h, exosomes 
were washed off and the medium was replaced. 48 h post patient serum exosome exposure, 
substantial and comparable quantities of viral RNA were detected in supernatant of cells 
treated with treatment-naïve and treatment non-responder patient serum exosomes. (D) 
Exosomes were isolated from sera of HCV infected treatment naive patients by the anti-
CD63 immunomagnetic isolation method and co-cultured with PHH.  HCV RNA copy 
number at, or above the sample size limit of detection for patient serum exosomes resulted 
in log-scale increases in recipient primary hepatocyte HCV RNA levels (E) HCV viral 
particles and CD63 selected HCV exosomes were purified from sera of HCV infected 
patients. The isolated exosomes and free virus (MOI = 1) were used to infect primary human 
hepatocytes over the indicated time course. The results represent exosomes isolated from the 
sera of 4 different HCV infected treatment naive patients. The data is presented as mean ± 
SEM (p<0.05 was considered statistically significant). 
This figure is adapted from Bukong and Momen-Heravi et al., 2015, PLoS Pathog. 
 
3.2.3 Exosomes mediate CD81, SR-BI and APOE receptor-
independent transmission of HCV 
Given the HCV-loaded exosomes selectively purified by CD63 immunomagnetic methods 
resulted in comparable infectivity to HCV virions, we sought to explore how known surface 
markers of transmission are involved with the infectious potential of each fraction. Different 
molecules such as CD81, Scavenger receptor class B member 1 also known as SR-BI, APOE 
and HCV glycoproteins E1 and E2 (HCV E1/E2) have been identified as important host and 
viral molecules for the mediation of HCV infection (Rice, 2011). It has been shown that anti-
CD81 and anti-HCV E1/E2 antibodies failed to completely block HCV infection, indicating 
alternative mechanisms of HCV transmission might exist (Morin et al., 2012; Meuleman et 
al., 2008). These findings lent support to our evidence that exosomes might provide the 
alternative route of virus transmission. Thus, we assessed whether the presence of anti-CD81 
antibodies would prevent exosome-mediated or cell-free virus transmission of HCV. 
 
Here, the capacity of culture-derived HCV virions to infect Huh 7.5 cells was reduced by up 
to 6 logs in the presence of an anti-CD81 Ab, as determined by resulting HCV RNA levels 
in recipient cells; in contrast, the effect on HCV-infected Huh 7.5 cell exosomes was only ~ 
1 log and not statistically significant (Figure 3.15A). The effect was mirrored in terms of 
viral protein production levels (Figure 3.15B), where the 6 log difference in RNA levels 
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translated in undetectable virus protein levels by Western blotting. These results were 
reproduced in primary human hepatocytes with either patient-derived exosomes and virus or 
culture-derived infectious particles (Figure 3.15C&D). Furthermore, SR-BI and APOE 
antibody pre-treatment prevented culture-derived virus from transmitting into naïve Huh 7.5 
cells, but had no impact on the infectivity of culture-derived HCV exosomes (Figure 
3.15E&F). Taken together, these studies defined the functional differences in infectious 
potential between exosomes and virions obtained from HCV-infected cells (whether patient- 
or culture-derived), and validated the efficacy of the purification methodology in positively 
purifying virus-free exosomes by CD-63 immunomagnetic methodologies. 
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Figure 3.15: Exosomes from HCV infected Huh7.5 cells and HCV patients transmit HCV 
and induce active infection in the presence of anti-SR-BI, anti-CD81, and anti-APOE 
antibody. (A, B) Huh 7.5 cells were pretreated with CD81 antibody (1:50 dilution) or not 
pretreated, as indicated. Huh7.5 cells were infected with HCV J6/JFH-1 virus or with 
exosomes purified from culture supernatants of HCV J6/JFH-1 infected Huh7.5 hepatoma 
cells. After 8 h of co-culture, viruses and exosomes were washed off and fresh culture 
medium was added to the cells, followed by 40 h further incubation at 37 °C. Total protein 
and RNA were extracted from the cells and analyzed by (A) qPCR for HCV RNA showed 
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transmission of HCV RNA via HCV exosomes in the presence of CD81 antibody (B) 
western blotting (WB) for HCV non-structural protein 3 (NS3) showed presence of viral 
NS3 protein in the recipient cells after co-culture with HCV exosomes in the presence of 
CD81. (C & D) Exosomes isolated from sera or free HCV virus from treatment naïve patients 
were co-cultured with primary human hepatocytes, along with anti-CD81 antibody pre-
treatment. Cells were lysed after 48 h and total RNA and proteins were harvested for HCV 
RNA quantification by a quantitative RT-PCR and by western blot for virus NS3 protein. 
An identical amount of infectious cell-free virus and HCV exosomes (MOI of 1) were used 
for all infections. HCV exosomes from isolated from treatment naïve patients transmitted 
infected to primary human hepatocytes in the presence of CD81 antibody.  (E&F) Huh 7.5 
cells were pretreated with anti-SR-BI antibody (1:50 or 1:100 dilution) or anti-APOE 
antibody (1:50 dilution) at different concentrations 1 h before infection. Huh7.5 cells were 
co-cultured with HCV J6/JFH-1 derived exosomes or free HCV J6/JFH-1 viruses for 48 h. 
Total RNA and protein was then extracted from the cells and analyzed for HCV RNA by 
qPCR. Protein extracts were analyzed by western blot for HCV NS3 protein. Infectious HCV 
virus and infectious HCV-exosomes (both MOI of 1) were used for all experiments. HCV 
J6/JFH-1 derived exosomes transmitted HCV RNA in the presence of APOE and SR-BI 
antibodies. Results are average of three independent experiments and are presented as mean 
± SEM. p<0.05 was considered statistically significant. 
This figure is adapted from Bukong and Momen-Heravi et al., 2015, PLoS Pathog. 
 
3.2.4 MicroRNA-122 inhibitor can reduce HCV virus transmission 
Given the established role of miRNA-122 in HCV biology, the enrichment of miRNA-122 
in exosomes derived from HCV-infected cells in the presence of HCV genome (Figure 3.12), 
it was reasoned that miRNA-122 inhibitors might reduce HCV transmission via HCV-
bearing exosomes. To investigate this hypothesis, HCV-exosomes were transfected with a 
miRNA-122 inhibitor or control, washed and re-purified with CD63 magnetic beads and 
used for the infection of naïve Huh7.5 cells. This protocol resulted in a statistically 
significant 50 % reduction in miRNA-122 levels in the recipient Huh7.5 cells. In contrast to 
control inhibitor loaded exosomes, administration of miRNA-122 inhibitor loaded HCV 
exosomes resulted in a significant reduction in intracellular miRNA-122 levels in Huh7.5 
cells (Figure 3.16A). Specifically, reduced virus transmission, identified by decreased HCV 
NS3 protein, was found after infection of Huh 7.5 cells by HCV-exosomes loaded with the 
miRNA-122 inhibitor (Figure 3.16 B).  
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Figure 3.16: Inhibition of miRNA-122 within exosomes can reduce HCV transmission. (A) 
miRNA-122 inhibitor or control inhibitor complexed with Altogen liver specific in-vivo 
delivery reagent and were co-cultured with HCV exosomes for 20 min and exosomes re-
purified. HCV exosomes loaded with miRNA-122 inhibitor or not as indicated were then 
transferred unto Huh7.5 cells and co-cultured for 24 h. This protocol resulted in a statistically 
significant 50 % reduction in miRNA-122 levels in the recipient Huh7.5 cells. (B) Western 
blot analyses of HCV NS3 protein indicated reduced virus transmission. Results are obtained 
from at least three independent experiments. 
 
3.2.5 Inhibition of exosome-mediated HCV transmission via 
blockage of vacuolar-type H+-ATPase inhibitor 
Bafilomycin A1, a vacuolar-type H+-ATPase inhibitor, an inhibitor of endosomal 
acidification that prevents the final fusion step between the virus envelope and the 
endosomal membrane was reported to completely block the virus entry (Tscherne et al., 
2006). Previous work on HCV cell entry did not distinguish between exosomes and viral 
particles (Tscherne et al., 2006). In these studies, it was reported that vacuolar-type H+-
ATPase inhibitor could block both virion entry and subsequent infection. Interestingly, 
endocytic exosome uptake was shown to be a pH-dependent procedure in an experiment 
evaluating exosome trafficking by tumor cells (Parolini et al., 2009). On this basis, an 
experimental model was setup utilizing bafilomycin A1 to evaluate the effect of low pH in 
preventing HCV exosome uptake by Huh 7.5 cells. Indeed, bafilomycin A1 successfully 
inhibited both virion and HCV exosome in a dose-dependent fashion (Figure 3.17). 
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Figure 3.17: HCV transmission by exosomes and free virus can be blocked by vacuolar-
type H+-ATPase inhibitor (bafilomycin A1). (A, B)Dose-dependent inhibition of infectious 
HCV (J6/JFH-1) virion and exosome uptake by Huh 7.5 cells by a vacuolar-type H+-ATPase 
inhibitor. Bafilomycin A1 (BafA1) was incubated at different concentrations for 1 h and the 
equal number of HCV J6/JFH-1 exosomes or cell free HCV virus (1:1) as determined by 
NTA was subsequently used to attempt infection of Huh7.5 cells. 24 h later total RNA was 
extracted from the cells and analysed by qRT-PCR for HCV RNA. The data was averaged 
from three independent experiments. Bafilomycin A1 (25 nM to 100 nM) effectively prevent 
HCV infection by HCV J6/JFH-1 exosomes or cell free HCV virus. 
This figure is adapted from Bukong and Momen-Heravi et al., 2015, PLoS Pathog. 
 
Taken together, this research has shown that exosomes derived from HCV-infected Huh7.5 
hepatocytes and HCV-infected patients harbor HCV RNA and can induce active infection 
in primary human hepatocytes independently of CD81, APOE, and SR-BI. These HCV 
exosomes appear enriched in replication-competent HCV-RNA in complex with miRNA-
122, Ago2, and HSP90. Modulation of miRNA-122, or the modification of the intracellular 
micro-environment through inhibition of a vacuolar-type H+-ATPase (V-ATPase) 
significantly altered the capacity of cells to become infected by HCV exosomes. 
 
3.3 Exosome cargoes and biofluid miRNAs as cancer 
biomarkers 
The results indicating the role of exosomes/miRNA in the pathogenesis of different liver 
diseases were reviewed in section 3.1 and 3.2. Besides liver disease, the role of 
exosomes/miRNAs in cancer progression and diagnostics is a very active area of research. 
Here, the role of exosomes in a mouse tumor model and the utility of miRNA salivary 
biomarkers in oral squamous cell carcinoma diagnostics will be discussed (Momen-Heravi 
et al., 2014b; Balaj et al., 2014). 
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3.3.1 Circulating exosomes/EVs carry amplifications of c-Myc and 
EGFR in a mouse tumor model 
It has been suggested that cancer genotype changes such as gene mutations, transcriptome 
changes, amplifications, and epigenetic changes can be monitored through exosome/EV 
nucleic acid testing (Redzic et al., 2014). Two human tumor cell lines of medulloblastoma 
and epidermoid carcinoma which had amplications for the c-Myc and EGFR, respectively, 
were chosen for injection in immunocompromised mice. One month after injection of tumor 
cells to immunocompromised mice, the increased levels of transcripts for the human EGFR 
and c-Myc were reflected in circulating EVs in mice that had developed tumors. The 
expression level of both human c-myc and human EGFR correlated well with the 
amplification status in the original tumors. This data confirms the utility of EVs for the 
diagnosis of cancers. This finding supports the notion that circulating EVs might provide an 
easily accessible, informative and possibly causally linked substrate for cancer biomarker 
discovery and future treatment development.  
 
3.3.2 Salivary miRNA for the detection of oral Squamous cell 
carcinoma 
Biofluid miRNAs, including those recovered from human saliva, have recently drawn 
considerable attention as potential diagnostic biomarkers (Lin et al., 2015; Machida et al., 
2015; Xie et al., 2015). One of the challenges of salivary miRNA diagnostics is the lack of 
control groups and lack of suitable endogenous control (EC) for salivary miRNA 
normalization. My efforts thus focused on evidencing a suitable EC for salivary miRNA 
assays relevant to oral cancer patients (Momen-Heravi et al., 2014b). The differential 
expression patterns of miRNAs among 4 groups of patients with oral squamous cell 
carcinoma (OSCC), patients with OSCC in remission (OSCC-R), patients with oral lichen 
planus, and healthy individuals were examined by a genome-wide high-throughput miRNA 
microarray. 
 
In these studies, miRNA-191 was identified as a suitable endogenous normalizer since it 
showed minimal intergroup and intragroup variability across subject groups and pooled 
samples. Of the more than 700 miRNAs present in saliva, 13 miRNAs consistently showed 
statistically significant differential expression in OSCC patients when compared to healthy 
individuals. This signature included 11 under-expressed miRNAs (miRNA-136, miRNA-
147, miRNA-1250, miRNA-148a, miRNA-632, miRNA-646, miRNA668, miRNA-877, 
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miRNA-503, miRNA-220a, miRNA-323-5p) and 2 overexpressed miRNAs (miRNA-24, 
miRNA-27b). Interestingly, miRNA-136 was also under-expressed in OSCC vs. OSCC-R. 
However, miRNA-27b levels were also significantly higher in OSCC vs. OSCC-R and oral 
lichen planus. This pointed to miRNA-27b elevation as a suitable biomarker for the 
stratification of OSCC from OSCC-R and oral lichen planus. Since there is a lack of 
minimally invasive biomarkers for detection of oral cancer we assessed the discrimination 
ability of miRNA-27b to classify the patients with OSCC versus control healthy subjects.  
Indeed, the resulting receiver operating characteristic curve (ROC curve) indicated that at 
the optimal cutoff value for miRNA-27b in OSCC patients versus healthy individuals, the 
sensitivity and specificity were 85.7% and 100.0%, respectively, with an area under the 
curve of 0.96 (Figure 3.18). 
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Figure 3.18: Curve of receiver operating characteristic and area under the curve for 
diagnostic accuracy of miRNA-27b. (A, B, C) Receiver operating characteristic curve 
analysis using differentially expressed miRNA 27b (miRNA-27b) for discriminating oral 
squamous cell carcinoma (OSCC) patients from OSCC patients in remission (OSCC-R), oral 
lichen planus (OLP) patients, and healthy controls (HCs). (D) Box presenting the area under 
the curve, sensitivity, specificity, and 95% confidence interval for every comparison 
between groups. 
 
Although no study assessed the salivary biomarker utility of miRNA-27b in oral squamous 
carcinoma, miRNA-27b was reported to be correlated with other type of cancers which 
originate from epithelial cells. For example, miRNAs comprising the miR-23b/27b/24 
cluster were found to correlate well with metastatic potential in mouse and human breast 
cancer cell lines and was elevated in metastatic lung lesions in human breast cancer patients 
(Ell et al., 2014). High expression levels of miRNA-27a/b correlated with poor response to 
chemotherapy in patients with esophageal cancer. In vitro mechanistic studies showed that 
esophageal cancer cells cultured in supernatant of miRNA-27a/b-transfected normal 
fibroblast showed diminished chemo sensitivity to cisplatin, compared with cancer cells 
cultured in supernatant of normal fibroblast. MicroRNA-27a/b-transfected normal fibroblast 
showed α-smooth muscle actin (α-SMA) expression, a marker of cancer-associated 
fibroblasts (CAF) as well as increased production of transforming growth factor-β (TGF-β) 
(Tanaka et al., 2015).  
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3.4 Exosome-based delivery of RNA interference and 
targeted miRNA therapy 
Exosomes as natural nano-sized homogenous vesicles which can be used for drug delivery. 
Given their nanoscale size, and natural ability to deliver bio-macromolecules, we designed 
series of experiments to assess utility of exosomes in delivery of miRNA-155 mimic and 
inhibitor. MicroRNA inhibitors are synthetic, negatively charged miRNA target analogs, 
which are fully complementary, and have the ability to inhibit miRNAs function (Robertson 
et al., 2010). The negative charge of miRNA inhibitors necessitates the use of GDVs for 
delivery (Pecot et al., 2011). It has been shown that LPS induces miRNA-155 overexpression 
in RAW264.7 macrophages which results in the production of TNFα (Bala et al., 2011). 
Given the suggested role of miRNA-155 in LPS-induced TNFα production and the 
importance of macrophage inflammatory activation in different diseases we hypothesized 
that it might be useful to harness exosomes as vehicles to deliver a miRNA-155 inhibitor. B 
cells were chosen as source of exosome production since previous report documented 
excessive upon stimulation with CD40 and IL-4 (Saunderson et al., 2008). Moreover, our 
preliminary results suggested low endogenous level of miRNA-155 in stimulated B cells. 
 
3.4.1 Purification and characterization of B cell derived exosomes 
for miRNA targeted therapy 
B cell (M12.4) were stimulated with IL-4/CD40 and purified as described in Chapter 2. The 
mean diameters of the resulting exosomes were 98 nm (Figure 3.19A&B). The observed size 
and morphology were consistent with other reports in the literature (Atay et al., 2011). These 
exosomes expressed CD63 and CD81, but lacked GRP78 as identified by western blot 
(Figure 3.19C). The transmission electron microscopy (TEM) images showed the 
characteristic exosome morphology as observed in Figure 3.3 and size range of less than 150 
nm (Figure 3.19D). Notably, NTA analysis indicated that upon stimulation of B cells with 
IL-4/CD40, exosome release increased drastically, up to 200-fold (Figure 3.19E). 
 
RESULTS 
86 
 
Figure 3.19: Characterization of B cell derived exosomes. (A) The diameter of stimulated 
B cell-derived exosomes was identified by NanoSight (mean diameter 98 nm). (B) The 3D 
graph represents particle size versus intensity versus concentration (particles/ml) of 
stimulated B cell-derived exosomes. (C) Isolated exosomes from murine B cells (M12.4 
expressed exosomal markers, CD81 & CD63). (D) Transmission electron microscopy 
(TEM) image of B cell-derived exosomes showed the exosome morphology and a diameter 
of less than 150 nm. (E) The relative number of exosomes increased significantly after 
stimulation of B cells with IL-4&CD40 compared to the non-stimulated B cells (P<0.001). 
Results are obtained from three independent experiments. 
This figure is adapted from Momen-Heravi et al., 2014, Nanomedicine 
 
3.4.2 MicroRNA profile of B cell derived exosomes 
To determine the suitability of B cell-derived exosomes as drug delivery vehicles for 
miRNA-155 modulating oligonucleotides, we first assessed miRNA-155 baseline 
expression in B cells and B cell-derived exosomes under both control and IL-4/CD-40 
stimulation conditions. Interestingly, while intracellular levels of miRNA-155 were high in 
the stimulated B cells, the resulting exosomes had the lowest miRNA-155 level observed 
amongst these samples, at an exosome to stimulated parent B cell ratio of 1:54. (Figure 3.20). 
In contrast, the relative expression of miRNA-155 was comparable between RAW264.7 
cells and their exosomes. Of note, the levels of cellular miRNA-155 were comparable 
between macrophages and B cells, even upon stimulation. These findings indicated 
selectivity of miRNA sorting into exosomes and confirmed that stimulated B cell-derived 
exosomes are almost devoid of miRNA-155. On this basis, IL4/CD40-stimulated B cell 
RESULTS 
87 
exosomes appeared as potentially suitable delivery vehicles for miRNA-155-modulating 
therapy. 
 
 
Figure 3.20: MicroRNA-155 expression in different exosomes and parental cells. Baseline 
expression levels of miRNA-155 in naive B cells, naïve RAW264.7 macrophages, and IL-
4/CD 40-stimulated B cells and their exosomes was measured by qRT-PCR, normalized 
against spiked in Cel-39, signifying limited miRNA-155 sorting into stimulated B cell 
exosomes (p<0.05), further decreased compared to naïve B cell exosome miRNA-155 levels 
(p<0.001). The results are obtained from three independent experiments. (# indicates p < 
0.05 versus parental cells).This figure is adapted from Momen-Heravi et al., 2014, 
Nanomedicine 
 
3.4.3 Optimization of exosome loading by electroporation.  
As described in Chapter 1, exosome-based delivery workflows should be tailored to the 
target disease, the cargo and the parental as well as targeted cells (Wahlgren et al., 2012). 
The workflow for efficiently loading murine B cell (M12.4) exosomes with miRNA-155 
was defined and optimized ahead of delivering miRNA-155 mimics and inhibitors in vitro 
and in vivo. Electroporation-mediated loading of B cell-derived exosomes was optimized by 
comparison of different voltages, capacitance, and miRNA-155 mimic to exosome mass 
ratios, with loading quantified by TaqMan® qRT-PCR. Of the five voltages with a constant 
capacitance (100 μf) tested, 0.14 kV - 0.20 kV was significantly more efficient, with optimal 
loading achieved between 0.15-0.20 kV (Figure 3.21A). Under 150 kV, assessment of 
different exosome concentrations (0.25 to 3 µg/ml exosomal protein) indicated 0.5 μg/ml to 
1 μg/ml exosomal protein to 150 pmol miRNA mimic achieved optimal encapsulation 
efficiency (Figure 3.21B). 
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Figure 3.21: Optimization of electroporation conditions for loading of miRNA-155 mimic 
to exosomes. (A) Introduction of miRNA-155 to B Cell exosomes was performed using 
various voltages. Exosomes + miRNA-155 mimic without electroporation served as negative 
control. After administration of an electric pulse, exosomes were re-pelleted using 
Exoquick-TC™ and the encapsulation efficacy at different voltages was identified by 
detection of the relative amount of miRNA-155 mimic. Voltages of 0.14 kV, 0.15 kV, 0.16 
kV, and 0.20 kV were more efficient compared to a lower voltage (0.130 kV) (p<0.05). 
(*indicates p < 0.05 compared to the lowest voltage). (B) Different concentrations of 
exosomal proteins were introduced to the exosomes via electroporation. All other conditions 
were similar. In the presence of exosomal protein concentrations of 0.5 μg/μl to 1 μg/μl 
loading was most efficient. The efficiency of exosome loading significantly diminished at 
concentration of more than 1 μg/μl (p<0.001). Results are obtained from three independent 
experiments. (*indicates p < 0.05 compared to the lowest concentration) 
This figure is adapted from Momen-Heravi et al., 2014, Nanomedicine 
 
3.4.4 Recovery of exosomes after miRNA-155 loading: method 
optimization and comparison 
To compare different methods for the isolation of exosomes after electroporation and 
development of an optimized protocol, the same amount of exosomes was electroporated 
with the same amount of miRNA-155 mimic. Thus, loaded and control exosome 
preparations were treated with 1 unit RNase H for 1 h and re-isolated with the Exoquick™, 
ultracentrifugation, or immunomagnetic isolation methods and re-suspended in PBS 
followed by RNA isolation by Direct-zol™ RNA MiniPrep isolation kit as described in 
section 2.1.1 (Figure 3.22A). This study indicated Exoquick™ was the best isolation 
efficiency approach compared to the two other methods (Figure 3.22B); CD63 
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immunomagnetic selection method was also superior to ultracentrifugation for the isolation 
of exosomes. On the basis of applying optimized loading and isolation conditions, a miRNA-
155 mimic exosome loading efficiency of 55 % with standard deviation of 3.64% was 
achieved. 
 
 
Figure 3.22: Optimization of workflow for isolation of miRNA-155 mimic loaded 
exosomes. (A) The schematic experimental workflow for evaluating the effect of different 
isolation methods on exosome recovery. (B) Identical amounts of B cell-derived exosomes 
isolated with CD63 immunomagnetic beads were loaded with same amount of miRNA-155 
mimic by the electroporation technique and re-isolated with different methods (Exoquick-
TC, ultracentrifugation, and CD63 magnetic beads). Cel-39 was spiked in the samples and 
served as normalizer. Exoquick outperformed ultracentrifugation and CD63 
immunomagnetic isolation in vesicles recovery (p<0.05). Ultracentrifugation was 
significantly less efficient than CD63 immunomagnetic isolation (p<0.05). The data is 
represented as the mean value and SD (as error bars) of three independent experiments. 
(*represents p < 0.05 versus ultracentrifugation)This figure is adapted from Momen-Heravi 
et al., 2014, Nanomedicine 
 
3.4.5 Exosome-mediated delivery of exogenous miRNA-155 mimic 
into primary mouse hepatocytes in vitro. 
The harvested miRNA-155-loaded exosomes successfully delivered their cargo to primary 
mouse hepatocytes after a time course of 6 h co-culture. Delivery was evidenced by a more 
than 700-fold increase in intracellular miRNA-155 levels at 24 h post-exosomal transfection 
as measured by qRT-PCR (Figure 3.23) and was reproduced also in miRNA-155 KO mouse 
primary hepatocytes (Bala et al., 2015). 
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Figure 3.23: Delivery of miRNA-155 mimic to primary mouse hepatocytes via exosomes. 
Exosomes derived from B cells were loaded with miRNA-155 mimic utilizing optimal 
loading conditions. The miRNA-155 loaded exosomes and control inhibitor loaded 
exosomes were co-cultured with primary mouse hepatocytes (6h) followed by washing and 
media replacement. The levels of miRNA-155 were quantified by qPCR after 24 h. 
Exosomes successfully delivered miRNA-155 mimic to primary mouse hepatocytes 
(p<0.001). The PCR analysis was normalized by SnoRNA202 (internal normalizer). Results 
are obtained from three independent experiments. (* represents p<0.05 versus control cells) 
This figure is adapted from Momen-Heravi et al., 2014, Nanomedicine 
 
Furthermore, KC were isolated from miRNA-155 KO mice and were similarly treated with 
exosomes loaded with miRNA-155. The protocol successfully delivered miRNA-155. The 
data is suggestive of increase in pro-inflammatory responses after LPS challenge as 
evidenced by measurement of MIP2 mRNA, MCP1 mRNA, and MCP1 protein levels 
(Figure 3.24). Importantly, however, these markers exhibited no inflammatory response 
induction in the recipient cells on account of exosome use, as evidenced by the lack of 
cytokine mRNA and protein increases in the cells not treated with LPS. 
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Figure 3.24: Biological function of miRNA-155 delivered via exosomes in Kupffer cells. 
Kupffer cells were isolated from miRNA-155 KO mice as described in Chapter 2. Exosomes 
were loaded with miRNA-155 or control mimic and co-cultured with cells for 6 h. The 
culture media was removed and cells were washed 3 times with PBS to remove free-floating 
exosomes. LPS (100 ng/l for 6 h) was added to the pertinent experiment groups. (A) The 
expression levels of miRNA-155 were quantified in the cells. The amount of miRNA-155. 
SnoRNA202 was used for normalization (B&C) Levels of MIP2 and MCP1 (mRNA) were 
quantified using real-time qPCR and levels were normalized to untreated cells. 18S was used 
for normalization of mRNA to account for the technical variations between the samples. (D) 
MCP1 protein levels were quantified in the cell-free supernatant. Results are obtained from 
three independent experiments. (ns: non-significant; * p<0.05 scrambled loaded exosome 
treated cells, # compared to scrambled loaded exosome + LPS treated cells.) 
This figure is adapted from Bala et al., 2015, Scientific reports 
 
RESULTS 
92 
3.4.6 Delivery of exogenous miRNA-155 inhibitor to macrophages 
using exosomes 
To evaluate the utility of B cell-derived exosomes for anti-miRNA delivery, B cell exosomes 
were loaded with miRNA-155 antisense inhibitor using the loading conditions defined for 
miRNA mimics. These successfully delivered miRNA-155 inhibitor to RAW 264.7 
macrophages as determined by qRT-PCR for miRNA-155, which is elevated in RAW264.7 
cells under LPS stimulation (Bala et al., 2011). Importantly, maximal miRNA-155 inhibition 
appeared to be superior with exosomal delivery systems as opposed to commercial 
transfection reagents (P<0.05), was not (empty) exosome mediated and inhibitor sequence 
dependent (Figure 3.25A). However, these data evidenced only effective association of the 
antisense with its target after an extraction-purification procedure; conceivably, this could 
be on account of post-purification annealing as opposed to intracellular on-target binding. 
As suppressor of cytokine signaling 1 (SOCS1) is a known target of miRNA-155 implicated 
in the LPS-mediated response of RAW264.7 cells (Kurowska-Stolarska et al., 2011; Davey 
et al., 2006), the levels of this transcript were therefore assessed to determine biological 
significance of these findings. Thus, >5x decrease in SOCS1 mRNA induced by LPS were 
reduced to a 2.5x decrease in the presence of miRNA-155 exosomes (Figure 3.25B). 
Significantly, the effect magnitude was substantially lower with commercial transfection 
reagents, which at best achieved 1.4X reduction. Again, these observations were not on 
account of (empty) exosome use or inhibitor sequence-independent. 
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Figure 3.25: Delivery of miRNA-155 inhibitor to RAW 264.7 cells via exosomes. 
Raw264.7 macrophages were plated 1 day prior to the experiments and different treatment 
conditions and controls were administered for 24 h. LPS (100 ng/ml) was administered to 
the cells for 6 h as indicated. (A&B) Relative expression of miRNA-155 and SOCS 1 were 
measured by quantitative real-time PCR (qPCR) using a TaqMan miRNA assay and CYBR 
Green PCR respectively. Results are obtained from three independent experiments. 
(*indicates p < 0.05 compared to medium + LPS treated RAW264.7 macrophages). 
This figure is adapted from Momen-Heravi et al., 2014, Nanomedicine 
 
In accordance with the expected mechanistic impact of SOCS1 restoration, exosome-
mediated miRNA-155 inhibition led to a significant decrease in LPS-induced TNFα protein 
(Figure 3.26). Significantly, the TNFα reduction achieved using exosomal miRNA-155 was 
statistically superior that achieved with commercial transfection reagents, not on account of 
(empty) exosome use and not inhibitor-sequence independent (Figure 3.26). The schematic 
of experiment design is depicted in Figure 3.27. 
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Figure 3.26: Exosome-mediate miRNA-155 delivery reduced TNFα levels in RAW264.7 
cells. Raw264.7 macrophages were plated 1 day prior to the experiments and different 
treatment conditions and controls were administered for 24 h. LPS (100 ng/ml) was 
administered to the cells for 6 h as indicated. The amount of TNFα protein in the supernatants 
was quantified by ELISA. Data was obtained from three independent experiments. Results 
are obtained from three independent experiments. (*indicates p < 0.05 compared to medium 
+ LPS treated RAW264.7 macrophages)This figure is adapted from Momen-Heravi et al., 
2014, Nanomedicine 
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Figure 3.27: B cell-derived exosomes were used as vehicles to deliver exogenous miRNA-
155 mimic or inhibitor into hepatocytes or macrophages. Exosomes loaded with a miRNA-
155 mimic successfully delivered miRNA-155 mimic and significantly increased miRNA-
155 levels in primary mouse hepatocytes and the liver of miRNA-155 knockout mice. 
Treatment of RAW264.7 macrophages with miRNA-155 inhibitor loaded exosomes resulted 
in a statistically significant reduction in LPS-induced TNFα production and partially 
prevented LPS-induced decrease in SOCS1 mRNA levels.  
 
3.4.7 Evaluation of the cytotoxicity risk of exosome-delivered 
miRNA inhibitor therapies 
Specially designed cationic lipids, such as the Lipofectamine have shown acute toxicity and 
immunogenicity after administration for nucleic acid delivery (Al-Dosari and Gao, 2009). 
Although viral vectors are believed to have less toxicity compared to cationic lipids, in a 
clinical trial for hemophilia B, an unexpected liver toxicity was observed and was attributed 
to a cytotoxic-T-lymphocyte response to adeno-associated virus serotype 2 (AAV-2) 
transduced hepatocytes (Manno et al., 2006). An ideal delivery vehicle should have high 
efficacy and minimal toxicity. Therefore, cytotoxic potential of exosome-delivered miRNA 
inhibitor therapeutics was explored alongside that of commercially available transfection 
reagents. To this end, the LDH release assay was used as a measure of cell lysis against 
known cytotoxic agents (staurosporine) (Lovborg et al., 2004). Importantly, exosome-based 
delivery of synthetic miRNA-155 antisense inhibitors or scrambled oligonucleotides showed 
no cytotoxic potential. However, in stark contrast, both of the commercially available 
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transfection reagents FuGENE® HD and HiPerFect showed statistically significant 
cytotoxicity (Figure 3.28). 
 
 
Figure 3.28: Evaluating cytotoxicty of exosome-based nucleic acid delivery and 
transfection reagents. LDH showed minimal cytotoxicity of exosomes compared to the 
transfection reagents and other controls after 36 h of co-culture. 20 nM staurosporine was 
used as a cytotoxic positive control. Results are obtained from three independent 
experiments. (*indicates p < 0.05 compared to non-treated macrophages) 
This figure is adapted from Momen-Heravi et al., 2014, Nanomedicine 
 
3.4.8 In vivo delivery and biodistribution of exogenous miRNA-155 
mimic via exosomes  
Several lines of evidence indicate that circulating miRNAs can be distributed into organs via 
the circulation (Kosaka et al., 2010; Minami et al., 2014). MicroRNAs are also receiving 
interest given their potential as therapeutic tools and targets in various diseases (Tiberio et 
al., 2015; Soifer et al., 2007). Evidences suggest that exosomes/EVs carry various molecular 
cargos including mRNA and non-coding RNA and can shuttle material between cells/organs 
(Eldh et al., 2010). MicroRNA-155 is an inflammation associated miRNA that control 
inflammatory responses and immune cell functions at multiple levels (O'Connell et al., 
2012).  We found that under a combined CpG+LPS inflammatory stimulus protocol, 
miRNA-155 was released into circulation and was strongly associated with EVs in the 
plasma of wild type mice (Figure 3.29A). We next proceeded to assess the half-life and 
biodistribution of ectopically produced exosomes associated with synthetic miRNA mimics 
in vivo. Thus miRNA loading of B cell exosomes generated using the optimized production 
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and electroporation protocols resulted in ~500x higher levels of miRNA-155 in the vesicles 
(Figure 3.29B). These were administered intravenously in miRNA-155 KO mice (100 μl; 
~2 × 108 particles, or 100 μg exosomal protein) and their resulting bio-distribution was 
determined across 6 key tissues after perfusion, to focus on parenchymal tissue loading 
(Figure 3.29C-H). 
 
 
Figure 3.29: Natural and ectopic exosomal delivery of miRNA-155. (A) Saline or 2.5 mg/kg 
CpG DNA were injected to C57Bl/6 wild type (WT) female mice. The mice were injected 
(with i.p.) once a day for three days. On day 4, CpG treated mice received 0.5 mg/kg LPS 
for 3 h, after which blood was collected. Exosomes were purified from plasma using a 
filtration+ExoQuick technique as described in Chapter 2. miRNA-155 levels were 
determined by TaqMan qPCR. (B) B cells were stimulated with CD40 and IL-4 and 
exosomes were purified using CD63 magnetic beads as described Chapter 2. The exosomes 
were electroporated with either miRNA-155 mimic or scrambled mimic. miRNA-155 levels 
were quantified after RNase H treatment. 100 µl of miRNA-155 analogue-loaded exosomes 
was injected intravenously into miRNA-155 KO mice for the indicated times and the levels 
of ectopic, exosomally-derived miRNA-155 in the plasma (C), liver (D), adipose tissue (E), 
lung (F), muscle (G), kidney (H) were quantified using real-time qPCR. miRNA-155 levels 
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were expressed relative to the miRNA-155 levels in the wild type saline treated mice. 
Synthetic spiked cel-miRNA-39 was used to normalize the variation between samples in 
exosome samples before RNA extraction (A–C). SnoRNA202 was used to normalize the 
technical variations between the samples in different tissues (D-H). Results are obtained 
from three independent experiments. (*indicates p < 0.05 compared to scrambled mimic 
exosome treated KO mice) 
This figure is adapted from Bala et al., 2015, Scientific reports 
 
The protocol led to an approximately 15-fold increase in miRNA-155 levels in plasma after 
5 min as compared to naturally occurring plasma miRNA-155 levels in wild type (WT) mice 
(Figure 3.29C) and peak tissue loading at approximately 10 min after injection. By 30 min 
post-injection, miRNA-155 levels had decreased substantially in plasma to match baseline 
miRNA-155 levels in WT mice (p=0.7) (Figure 3.29C). Notably, miR-155 kinetics were 
similar across plasma and the tissues assayed (Figure 3.29D-H), with accumulation being 
liver>adipose tissue>lung>muscle>kidney as compared to baseline miR-155 levels in WT 
animals. Interestingly both the liver and adipose tissue accumulated higher than baseline 
amounts of miRNA-155 mimic within 10 min, but regressed to the baseline WT expression 
levels after 40 min and disappeared after 4 h. In stark contrast, no significant increase in 
miRNA-155 was observed in the brain, heart, spleen, bone marrow cells or thymus. 
Importantly, across this study the observed miRNA-155 fluctuations were mimic-sequence 
specific as evidenced through use of scrambled sequence controls. 
 
To scrutinize further the cellular distribution of exosomal miRNA-155 in the liver, the 
ectopic miRNA-155 was quantified in hepatocytes and liver mononuclear cells (MNCs) of 
KO mice.  Peak levels were observed at 10 min following injection followed by a rapid 
decline, similar to what perfused liver observations (Figure 3.30). However, neither cell type 
appeared to accumulate miRNA-155 to levels comparable of those observed in WT mouse-
derived cells by a factor of 2-4x.  
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Figure 3.30: Cellular level distribution of exosome loaded miRNA-155 mimic in miRNA-
155 KO mice. After in vivo delivery of miRNA-155, hepatocytes (A) and mononuclear cells 
(B) were isolated and miRNA-155 levels were determined using a real time qPCR. miRNA-
155 levels were normalized to the wild type saline treated mice. SnoRNA202 was utilized 
to normalize the technical variations between the samples. Results are obtained from three 
independent experiments. (*indicates p < 0.05 versus scrambled mimic exosome treated KO 
mice; p<0.05 is considered statistically significant) 
This figure is adapted from Bala et al., 2015, Scientific Reports 
 
Interestingly, unlike other biological and synthetic delivery systems, miRNA exosome co-
culture with liver MNCs isolated from wild type mice did not induce any pro-inflammatory 
cytokines in this study (TNFα, MCP1 and IL-1β) both at the mRNA and protein levels in l 
(Figure 3.31). 
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Figure 3.31: Scrambled mimic loaded exosomes do not elevate inflammatory markers in 
liver mononuclear cells. (A) Scrambled mimic loaded exosomes were co-cultured with the 
liver mononuclear cells isolated from WT mice for 6 h. Free-floating exosomes in the 
supernatant were removed and cells were cultured for another 6 h. The mRNA expression 
levels were determined by real-time PCR (B) Cell-free supernatants were used to measure 
protein levels of MCP1, TNFα, and IL-1β by ELISA. Results are obtained from three 
independent experiments. In both graphs, the dark bars demonstrate the scrambled mimic 
loaded exosomes and the light bars demosntrate the untreated controls. 
This figure is adapted from Bala et al., 2015, Scientific Reports 
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Discussion 
Research on EVs and the role of noncoding RNA has been growing exponentially during the 
past few years. Exosomes are found in different biofluids and are potential sources for the 
discovery of novel biomarkers. Although exosome research is growing very rapidly, there 
remain major challenges in terms of reproducible isolation and characterization of exosomes, 
understanding role of exosomes in various pathological pathways, and assessing the utility 
of exosomes as drug delivery vehicles. My research first aimed to establish and compare 
methods for isolation and characterization of exosomes (Momen-Heravi et al., 2013; 
Momen-Heravi et al., 2012a; Momen-Heravi et al., 2012b). Secondly, my research explored 
the functional role of exosomes and miRNAs in the pathogenesis of different diseases 
including alcoholic hepatitis (Momen-Heravi et al., 2015a), hepatitis C (Bukong et al., 
2014), and head and neck cancer (Momen-Heravi et al., 2014b). The result of my 
investigations identified pathways and new disease mechanism and introduced new 
diagnostic potential. Thirdly, my research explored the bio-distribution of exosomes and 
miRNA (Bala et al., 2015), and potentials for using exosomes as drug delivery vehicles 
(Momen-Heravi et al., 2014a). This resulted in an establishment of a workflow and new 
approaches for harnessing the delivery potential of exosomes to pursue miRNA/RNA 
targeted therapies in both in vitro and in vivo models. In this chapter, I will discuss some of 
the main findings of my research, which demonstrate a conceptual overview of my work in 
the field of exosomes/EVs and RNA biology. Future directions in the RNAi and 
exosomes/EVs field and its challenges are also considered. 
 
4.1 Isolation and Characterization  
One of the main issues in using exosomes for biomarker discovery and as drug delivery 
vehicles is the lack of reproducible and reliable methods of isolation and characterization. 
In several cases, small variation in structure or isolation techniques can lead to substantial 
downstream biological or analytical effect. For instance, phosphorothioate backbone 
modification of nucleotide-based drugs is a common modification performed to increase 
stability and prevent degradation of nucleic acids by plasma and intracellular nucleases. A 
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new reported documented unexpected effect of phosphorothioate backbone modification in 
triggering robust platelet activation and ROS generation (Flierl et al., 2015). In the RNAi 
studies, a great body of studies fail to rule out, off-target effects by employing proper 
negative and positive controls (Cook et al., 2014). In  the exosome field, performing 
unadjusted protocol for rotor with lower k-factor lead to lower substantially lower yield of 
RNA and proteins (Cvjetkovic et al., 2014). In fact, such methods should be tailored based 
on the specific to the biofluid in question and the downstream (therapeutic or diagnostic) 
target. In addition to the necessity of method optimization, the effect of each alteration in 
downstream results should be fully understood and considered as part of ongoing 
improvement in nucleomic and exosome field.  
 
In this domain, my research demonstrated that the viscosity of biofluids could significantly 
affect sedimentation efficiency after ultracentrifugation (Momen-Heravi et al., 2012b). We 
observed a significant difference between sedimentation efficiency of plasma, serum and 
culture media (p < 0.001) after employing identical ultracentrifugation protocol and 
condition. The viscosity of the plasma, serum, CM, and PBS were 1.65, 1.4, 1.1, and 1.0 cP, 
respectively. The Pearson correlation was −0.912 (p < 0.001), indicating that a greater 
viscosity leads to lower sedimentation efficiency (Momen-Heravi et al., 2012b). Also, we 
found that in more viscous biofluids, particles with larger diameters had a tendency to 
sediment after ultracentrifugation rather than smaller ones. These results have influenced 
significantly the approach taken by groups working in this area, who now incorporate 
normalization of viscosity in their isolation protocols of EVs (Witwer et al., 2013; Lobb et 
al., 2015; Taylor and Shah, 2015). Thus, this work has seeded the necessary level of 
standardization pertinent to clinical use of exosomes either as diagnostic or therapeutic tools.  
 
4.2 Role of exosomes and miRNAs in the pathogenesis 
of alcoholic liver disease 
Extracellular vesicles including exosomes exert different physiological and pathological 
functions that have been described extensively in the literature (Yanez-Mo et al., 2015; 
Yuana et al., 2013). My research resulted in novel findings revealing the role of exosomes 
and miRNAs in the pathogenesis of alcoholic liver disease (Momen-Heravi et al., 2015a). 
As with many cancer studies, this work found that the total number of exosomes was 
increased in an in vitro model of ethanol administration, in human subjects after binge 
alcohol drinking, as well as in murine models of chronic alcohol feeding and binge alcohol 
feeding. Furthermore, a significant increase in the expression level of Rab 27b was 
consistently observed in hepatocytes after administration of ethanol. Mechanistically, this 
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finding is in line with the elevation of exosome production observe, as Rab 27b is part of the 
family of Rab membrane bound proteins which play crucial roles in vesicular trafficking and 
fusion at the plasma membrane (Ostrowski et al., 2010). Thus, my work has helped 
corroborate the link between the cellular effects of ethanol on multivesicular body formation 
and exosome production, and expand understanding of the fundamental processes 
underpinning these phenomena. 
 
Beside an increase in the total number of exosomes, this work also reported significantly 
elevated exosomal miRNA-122 levels in all in vivo models and in an in vitro setting, 
suggesting an alcohol-mediated activation of the exosome production machinery in 
hepatocytes, associated with miRNA-122 sorting into these vesicular bodies. Interestingly, 
it has been reported that miRNA-122 could be related to liver injury, and elevated levels 
were found in acetaminophen (paracetamol)-induced liver injury and Toll-like receptor 
(TLR) 9+ 4 ligand-induced inflammatory cell mediated liver injury (Bala et al., 2012). 
However, the function of exosomal miRNA-122 as the product of liver injury remained 
unclear.  
 
Given the role of monocytes in acute liver injury and inflammatory disease (Zimmermann 
et al., 2012), my efforts focused on exploring the functional potential, if any, of hepatocyte 
derived exosomal miRNA-122 in these cells. These studies revealed that monocytes, which 
are almost devoid of miRNA-122, actively collected these exosomes (Momen-Heravi et al., 
2015a) to modulate their immune function through sensitization to LPS and an increase in 
pro-inflammatory cytokine production through modulation of HO-1 expression and its 
reciprocal target, Nox2. The HO-1 pathway is a pivotal immune surveillance pathway, which 
is necessary for cell survival and cell plasticity after challenges with LPS and ROS (Yachie 
et al., 2003; Li et al., 2012b; Taille et al., 2004). Mice deficient for HO-1 show increased 
pro-inflammatory responses, increased cellular necrosis, and increased mortality after LPS 
challenge (Gozzelino et al., 2010; Poss and Tonegawa, 1997), findings aligned with the 
observed functional outcomes of exosomal miRNA-122 uptake by monocytes. Crucially, the 
observed increase in monocyte miRNA-122 levels was only due to the horizontal transfer of 
the mature miRNA-122: pri-miRNA-122 was undetectable in these cells suggesting no de 
novo expression and synthesis of this non-coding RNA (Momen-Heravi et al., 2015a). 
 
Taken together, these findings demonstrate a novel mechanism of cross-talk between 
ethanol-exposed hepatocytes and naïve monocytes via exosomes and their small non-coding 
RNA contents, specifically the hepatocyte specific miRNA-122. Moreover, these 
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observations provide a possibly additional mechanistic basis for the previously reported pro-
inflammatory phenotype or M1 phenotype in non-resident immune cells and KC; thus, 
production of augmented pro-inflammatory cytokines and ROS may not only be instigated 
by alcohol and its metabolites, but also by paracrine activity of miRNA-122 containing 
exosomes derived from injured hepatocytes after alcohol exposure. 
 
In addition to well-studied direct alcohol induced damage (Gao and Bataller, 2011), immune 
modulation through exosome-mediated transfer of miRNA-122 and modulation of the HO-
1 pathway could be another mechanism of hyper-sensitization of monocytes/macrophages 
to LPS, which is observed in alcoholic liver disease (Momen-Heravi et al., 2015a). 
Importantly, exosomes loaded with miRNA-122 inhibitors were able to therapeutically 
attenuate the miRNA-122 mediated pro-inflammatory phenotype in monocytes. The precise 
therapeutic potential of such interventions remains to be described given the promising 
results observed with unformulated (naked), highly modified miRNA-122 antisense in the 
clinic (Miravirsen)(Janssen et al., 2013) (Lee et al., 2014). Miravirsen (Santaris Pharma, 
Copenhagen, Denmark), showed promising results in dose dependent reduction of HCV 
RNA in chronic HCV genotype 1 infection levels without evidence of viral resistance in a 
phase 2 clinical trial (Janssen et al., 2013). Thus, whilst transient impairment of the use of 
miRNA-122 by Hepatitis C and in hepatocyte metabolism has been suggested, it remains to 
be determined if chronic attenuation of the monocyte-mediated pro-inflammatory status 
might offer protective functions to alcoholic liver disease or other chronic conditions 
characterized by inflammation-induced liver fibrosis. Significantly, whilst miravirsen 
targets principally hepatocytes(Gebert et al., 2014), exosomal delivery of anti-miRNA-122 
might access, and potentially even specifically target the monocyte subpopulation in the 
future, thereby expanding the utility of such interventions and minimizing impact to the 
canonical role of hepatocytes. These findings therefore open a new horizon in understanding 
the role of exosomes and highlight the potential utility of RNA-interference-associated 
therapeutics in the management of alcoholic liver disease. 
 
4.3 Exosomes play an active part in Hepatitis C 
transmission 
Specifically within the context of HCV, this research has demonstrated that circulating 
exosomes isolated from sera of a) treatment-naïve, HCV-infected subjects or b) HCV 
treatment non-responder individuals contain replication-competent HCV virus (Bukong et 
al., 2014). Importantly, several steps have been taken to ensure these findings are specific to 
exosomes and not potentially contaminating virions in establishing that these exosomes can 
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transmit active HCV infection to primary human hepatocytes. Thus, a novel approach 
consisting of serial filtration in combination with polymer precipitation and immune 
magnetic CD63- positive exosome isolation has been adopted to successfully and adequately 
separate exosomes from viral particles. Furthermore, the resulting viral genome titres in the 
recipient cells is increased by up to 3 logs in primary human hepatocytes compared to the 
exosomal load, indicative of active replication. 
 
In addition to the purification approach, mechanistic evidence supports the premise that 
HCV-containing exosomes appear to mediate virus transmission, as SR-BI, CD81, and 
APOE -independent mechanisms were implicated. CD81 is a member of the tetraspanin 
family and one of the first identified entry receptor for HCV (Pileri et al., 1998). The class 
B scavenger receptor (SR-BI) protein was initially identified as a high affinity low density 
lipoprotein (LDL) receptor; SR-BI is HCV cellular receptor and play a significant role in in 
the early steps of HCV infection (Sabahi, 2009). APOE is required for HCV virion 
infectivity and HCV virions are assembled as APOE-enriched lipoprotein particles (Chang 
et al., 2007). Interestingly, this might explain the potential efficacy of HCV immunotherapy 
in some patients. A study by Wilson et al (Wilson et al., 2011), showed that bonding of Ago2 
and miRNA-122 to 5′-UTR of HCV dsRNA enhances HCV replication. Within exosomes 
harvested from patients and HCV-infected cultured cells, HCV RNA was associated with 
HSP90, miRNA-122, and Ago2. Thus, experiments were designed to analyze the therapeutic 
potential of miRNA-122 inhibition with respect to exosome-mediated transmission. In these 
studies, miRNA-122 inhibitor modulated exosome function and significantly decreased 
exosome-mediated HCV transmission. 
 
Exosomes originate from the lumen of MVBs and their cellular uptake and release is 
associated with the endocytic pathway (Urbanelli et al., 2013). The vacuolar H+-ATPases 
(V-ATPases) and proton pumps generate and maintain intra-cellular pH gradients across cell 
membranes. Impaired function of V-ATPases was reported to be accompanied by lysosomal 
dysfunction and impaired endocytosis (Jentsch et al., 2005; Vingtdeux et al., 2007). In line 
with these findings, the therapeutic potential of a vacuolar-type H+-ATPase inhibitor and a 
proton pump inhibitor was also evaluated and was shown to able to block exosome-mediated 
and free virus mediated transmission of HCV to Huh 7.5 hepatoma cells. 
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4.4 Exosome-mediated delivery, biodistribution of 
miRNAs, miRNA targeted therapy  
4.4.1 In vivo biodistribution of miRNA-155 
The clinical potential of any novel pharmacological approach, whether consisting of a 
biological, a chemical or genetic drug, pivots on absorption, distribution, metabolism and 
elimination kinetics in vivo. In line with these requirements and on the basis of the promising 
findings of exosomally-delivered miRNA and their antisense inhibitors, the bio-distribution 
and half-life profiles of this novel chemobiologic formulation was investigated (Bala et al., 
2015). Intravenously-administered exosomes loaded with miRNA-155 mimic underwent 
rapid distribution across various, but not all of the organs of recipient mice, in what appeared 
to be a plasma circulation mediated fashion. Use of the miR-155 KO animals against their 
WT counterparts enabled comparative enumeration of the extent of tissue and cell tropism 
as well as some preliminary insight on the duration of tissue residence. Thus, the level of 
ectopically provided miRNA-155 was found to acutely exceed normal (WT) levels in the 
liver and adipose tissue, but also reached in appreciable quantities the lung, muscle, and 
kidney. In accordance with these study, other work has reported the highest concentration of 
fluorescently-labeled, ectopically produced exosomes to be reached in the liver, lung and 
spleen 1 h after i.p. administration (Sun et al., 2010; Zhuang et al., 2011). Significantly, 
ectopic miRNA-155 was delivered to hepatocytes and liver MNC in vivo, supporting the 
utility of these vesicles in liver-targeted RNAi modulating therapies. Likewise, in agreement 
with other work (Zhuang et al., 2011; Alvarez-Erviti et al., 2011), no significant 
accumulation of exosome-related miRNA-155 was observed in the brain, suggesting 
exosome modification (e.g. targeting or blood-brain-barrier relaxing moieties) could be a 
likely necessity for access across the blood-brain barrier. Taken together, the differential 
bio-distribution profile across the surveyed tissues indicates the perfusion protocol 
effectively eliminated circulatory exosomes to enable tissue and cell-association data to be 
reliably obtained.  
 
In the contexts of both basic research and clinical practice, RNA biology has been 
revolutionized through the unveiling of the significant role non-coding RNAs play in 
physiology and disease, and by the promise of RNA-based/targeting therapeutics. These 
novel drugs encompass the RNAi, synthetic/in vitro transcribed RNA sequences, miRNA 
mimics and miRNA inhibitors. Beyond the miRNA-122 inhibiting Miravirsen, ALN-RSV01 
(Alnylam pharmaceuticals, Cambridge, Massachusetts), which is a naked siRNA targeted 
against respiratory syncytial virus (RSV) nucleocapsid, showed promising results in the 
prevention of bronchiolitis obliterans syndrome respiratory syncytial virus infections in lung 
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transplant patients at phase 2b. (Gottlieb et al., 2016). However, the fact that most forms of 
RNA are prone to rapid degradation by RNases, are negatively charged, and are potentially 
immunogenic have repeatedly obstructed their commercial success and clinical use. 
Different nucleic-acid delivery modalities, including viral and non-viral vectors, and 
transfection reagents are already broadly used for in vitro and in vivo delivery, even onto 
generating genetically modified cell-based therapies (Sharpe and Mount, 2015). 
Nevertheless, direct treatment (i.e. not cell based) approaches with the exception of arguably 
only one exception (UniQure) have suffered setbacks especially when associated with 
repeated administration (Marcus and Leonard, 2013). 
 
4.4.2 Exosome-mediated delivery 
Exosome-mediated delivery of miRNAs and RNAi has several advantages. Firstly, 
exosomes can be isolated from the recipients’ own biofluids and stably stored for a 
prolonged time, for subsequent loading of biological drugs when required (Sokolova et al., 
2011). Proof of clinical and commercial principle for such an autologous biological therapy 
approach has been delivered through Strimvelis, however the breadth of personalized 
exosome biobanking, purification or ectopic modification that might be necessary to achieve 
maximal tissue and disease coverage remains to be determined. Secondly, based on the 
preliminary research presented here, exosomes do not induce any inflammatory response, 
either in vitro or in vivo. Although preliminary such data have delivered tremendous 
excitement in the past, periodically new mechanisms of immune system activation suggest 
caution and further work on fully dissecting the immunomodulatory potential of specific 
exosome preparations (Broering et al., 2014; Forsbach et al., 2008). Moreover, the evidence 
produced through this work indicates efficacy dissociated from the toxicity inherent to other, 
widely used drug delivery modalities. These data are very encouraging for processes that are 
routinely in use in the laboratory, but require expansion on other mechanisms of cell injury 
ahead of further use. Thirdly, as with viral and non-viral competition, exosomes can protect 
the miRNA and RNAi cargo from degradation by RNases; indeed, the comparative stability 
of the delivery system, the cargo and the complex, both in wet and potentially even dry 
formulations in the future needs to be established.  
 
It has been shown that EVs and exosomes can naturally transfer a variety of functional 
macromolecules, including mRNA, miRNA, and genomic DNA and the possibility of 
harnessing exosomes for the delivery of bio-macromolecules is an attractive approach 
(Valadi et al., 2007; Crescitelli et al., 2013; Montecalvo et al., 2012; Seow and Wood, 2009). 
Nevertheless, the efficiency of exosome-mediated delivery must be optimized based on the 
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recipient cell type, target cargo and exosome type, since the exosomal cargo is selectively 
enriched and exosomes have different natural abilities for drug delivery (Valadi et al., 2007; 
Crescitelli et al., 2013). In this research, the loading conditions for B cell-derived exosomes 
were first optimized to explore their use for nucleic acids delivery (Momen-Heravi et al., 
2014a). Upon stimulation of B cells with IL-4 and CD40, large quantities of exosomes were 
produced, suggesting scalability of the approach to industrial grade production. Indeed, this 
has been a pivotal requirement in translating antibody therapeutics from successful 
laboratory reagents into quality of life transforming therapies. 
 
Thus, using optimized conditions, B cell-derived exosomes were able to effectively deliver 
a miRNA-155 inhibitor into RAW264.7 macrophages, causing inhibition of miRNA-155, 
and subsequent functional decrease of TNFα production (Momen-Heravi et al., 2014a). In 
comparison with conventional transfection reagents (FuGENE HD and HiPerFect) this 
inhibitory efficacy was not accompanied by any, even marginal degree of cytotoxicity. These 
results therefore support expansion of this approach to other high clinical demand / unmet 
need disease areas, such as neurological disorders, cancers, and autoimmune diseases where 
miRNA-155 is deregulated, or indeed other miRNAs and synthetic RNAi.  
 
Pivotal to achieving these findings was the development of an optimized A to Z workflow 
from exosome production, purification, electroporative loading, re-isolation and in vitro 
evaluation for B cell-derived exosomes (Figure 4.1). Presently, this protocol achieves a 55 
% loading efficiency for a miRNA-155 cargo, can eliminate free-floating / surface bound 
miRNA-155 and drug precipitation, and is the best performing approach out of three widely 
used solutions (ExoQuickTM, Immunomagnetic bead-based purification and 
ultracentrifugation). This addresses the low efficiency bottleneck in the use of exosomes for 
biomarker discovery and as drug delivery vehicles (Alvarez et al., 2012; Witwer et al., 2013; 
Marcus and Leonard, 2013),  
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Figure 4.1: Workflow of the use of exosomes for the delivery of miRNA-targeted 
therapeutics 
 
4.5 Exosomes and miRNAs as biomarkers in cancer 
New advances in high-throughput technologies designed for analyzing biospecimens, 
coupled with the recent breakthroughs in whole genome sequencing, transcriptome and 
proteome profiling technologies, has led to introduction of different disease biomarkers, 
including transcriptomics, proteomics, lipidomics and metabolomics (de Graaf, 2013; 
Kulkarni et al., 2010). EVs have reignited interest in the field of biomarker discovery, as 
they are effective carriers of cell communication signals, and are enriched in different 
nucleic acids and proteins (Jia et al., 2014). Saliva in particular has been introduced as a new 
biomarker discovery substrate, since it can be used as a potential non-invasive approach for 
early detection and monitoring of different diseases. 
 
The pivotal role of miRNAs in tumorigenesis as either tumor suppressors or oncogenes is 
well established (Jiang et al., 2015). In fact a high fraction of known miRNAs is located at 
fragile chromosomal sites or in cancer-associated genomic regions, including minimal 
regions of loss of heterozygosity or minimal amplicons (Calin and Croce, 2007). Based on 
these observations, whole genome miRNA screening was undertaken on different patient 
cohorts spanning OSCC, treated OSCC in remission, and oral lichen planus to find a reliable 
salivary biomarker for OSCC detection (Momen-Heravi et al., 2014b). The work revealed a 
reliable normalizer for saliva, miRNA-191, which showed the least inter group and intra 
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group variability. Furthermore, miRNA-27b was identified as a reliable miRNA for saliva-
based diagnosis of oral cancer, as underlined by high sensitivity, high specificity, and 
excellent diagnostic value for patient stratification. 
 
We also hypothesized that squamous cell carcinoma tumor amplifications might be 
detectable in circulation (Balaj et al., 2014). Two human tumor cell lines derived from a 
squamous cell carcinoma and a medulloblastoma, which had amplification for the EGFR 
and c-Myc genes, were implanted subcutaneously into immunocompromised mice. 
Transcript amplification in both groups of subcutaneous tumors was quantified and matched 
in circulating EVs in tumor-bearing mice, correlating well with parent gene amplification 
status in the tumors. This data provides further support to the notion that circulating EVs and 
biofluid miRNAs can serve as potential platforms for tumor biomarker identification and 
clinical use. 
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Conclusion 
As exosomes and extracellular vesicles gain further attention as major players in cell 
communication and as potentially causal, clinically-relevant biomarkers, quality assurance 
and method validation has become crucial. A significant part of my research addressed that 
issue and led to enhancement of associated isolation methods with detailed comparative 
evidence over techniques relating to B cell-derived exosomes. In the context of alcoholic 
liver disease, my research found a novel, exosome-mediated mechanism of cross talk 
between ethanol-exposed hepatocytes and normal monocytes involving horizontal transfer 
of miRNA-122 to augment pro-inflammatory conditions in monocytes. Mechanistically, this 
was linked to miRNA-122-mediated suppression of the HO-1 pathway, which might consist 
of an alternative mechanism of sensitization of monocytes and macrophages to intestinally 
derived LPS in alcoholic liver disease. The activation of inflammatory pathway may also be 
meditated through exosomal HSP90 and which is TLR4 agonist and can exacerbate liver 
damage in a positive feedback loop. Experimental research to evaluate this hypothesis is 
needed. Crucially, these studies have evidenced the therapeutic potential of exosome-
mediated RNAi modulator delivery beyond hepatocytes to the mechanistically implicated 
effector monocytes relevant to inflammatory liver disease. Thus, Exosomes loaded with 
miRNA-122 inhibitor were able to attenuate miRNA-122 mediated immune stimulation in 
monocytes. This is the first study to seek and evidence successful delivery to liver cell targets 
other than the first passage function of hepatocytes. 
 
Furthermore, this research elucidated a mechanistic role for exosomes in promoting HCV 
infection. Thus, novel exosome and virus isolation/separation method were developed, to 
sufficiently support the evidence that a) HCV-infected hepatocyte exosomes, as opposed to 
HCV virions, contained APOB and no APOE; b) replication competent HCV RNA was 
present in these HCV-infected hepatocyte exosomes produced both by patients and infected 
hepatocyte cultures; c)  The HCV exosomes mediated active virus transmission and 
replication in human hepatocytes and cell lines, even after pretreatment with a HCV virion 
receptor blocking antibody (anti-SR-BI, anti-CD81, anti ApoE); and d) that Ago2 and 
miRNA-122, both accepted enhancers of HCV replication and translation, were associated 
with the exosome-packaged HCV +RNA genome. We furthermore examined therapeutic 
approaches including vacuolar-type H+-ATPase and proton pump inhibition to show 
successful blockade of  exosome-mediated, and even free virus mediated transmission of 
HCV to Huh 7.5 hepatocytes.  
CONCLUSION 
112 
 
Collectively, this thesis puts in place the methodological basis for harnessing exosomes to 
deliver RNA cargos in vitro and in vivo, in a potentially non-toxic, non-immunogenic means 
with a broad scope of drug delivery and a robust approach to providing supporting evidence 
thereto. Furthermore, it has expanded evidence on the liquid biopsy promise offered through 
high diagnostic accuracy in the clinical setting.  In order to translate EV utility from a 
discovery tool to a reliable clinical solution, the standardized methodology implementations 
presented herein can be expanded to industrial-scale applications and quality control, in line 
with the commercial paradigm of other autologous cell based therapeutics. Mechanistic 
studies focused on further elucidating EV function through high-throughput ‘omic 
approaches in EV studies will be required to pave the way for understanding the affected 
pathological pathways and for developing personalized molecular therapy solutions.  
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Appendix: Table of primers 
Primers are organized by publication, following the numbering on page 8. 
Target Gene Forward Sequence Reverse Sequence 
Publication 1 
18 S 5′-GACCTCATCCCA CCTCTCAG-3′ 5′-CCATCCAATCGGTAGTAGCG-3′ 
human TNFα 5′-GAGTGACAAGCCTGTAGCCCATG 
TTGTAGCA-3′ 
5′-GCAATGATCCCAAAGTAGACCTG 
CCCAGACT-3′ 
human IL-1β 5′-CAGCTACGAATCTCCGACCAC-3′ 5′-GGCAGGGAACCAGCATCTTC-3′ 
human MCP1 5′-CCCCAGTCACCTGCTGTTAT-3′ 5′-TGGAATCCTGAACCCACTTC-3′ 
human Nox2 5′-GGGAAAAATAAAGGAATGCC-3′ 5′-AGCCAGTGAGGTAGATGTTG-3′ 
human HO-1 5′-ACCAACTGCTTAGCACCC-3′ 5′-GCAGAGAATGCTGAGTTCATG-3′ 
human GAPDH 5′-AGGGCTGCTTTTAACTCTGGT-3′ 5′-CCCCACTTGATTTTGGAGGGA-3′ 
mouse HO-1 5′-CTGTGTAACCTCTGCTGTTCC-3′ 5′-CCACACTACCTGAGTCTACC-3′ 
human Rab 27b 5′-TGCGGGACAAGAGCGGTTCCG-3′ 5′-GCCAGTTCCCGAGCTTGCCGTT-3′ 
Publication 2 
18S 5’-GTAACCCGTTGAACCCCATT-3’ 5’-CCATCCAATCGGTAGTAGCG-3’ 
mouse TNFα 5’-CACCACCATCAAGGACTCAA-3’ 5’-AGGCAACCTGACCACTCTCC-3’ 
mouse IL-1β   
mouse MCP1   
Publication 4 
18S 5′-GACCTCATCCCACCTCTCAG-3′ 5′-CCATCCAATCGGTAGTAGCG-3′ 
SOCS1 5′-GACCTCATCCCACCTCTCAG-3′ 5′-ACAAGCTGCTACAACCAG GG-3′ 
Publication 7 
EGFR 5’-TATGTCCTCATTGCCCTCAACA-3’ 5’-CTGATGATCTGCAGGTTTTCCA-3’ 
c-Myc 5’-CAACCCTTGCCGCATCCAC-3’ 5’-AGTCGCGTCCTTGCTCGG-3’ 
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